

# Nephronophthisis

**Synonym:** NPH

Marijn Stokman, MD, Marc Lillen, MD, PhD, and Nine Knoers, MD, PhD.

► Author Information

Initial Posting: June 23, 2016.

## Summary

---

**Clinical characteristics.** The nephronophthisis (NPH) phenotype is characterized by reduced renal concentrating ability, chronic tubulointerstitial nephritis, cystic renal disease, and progression to end-stage renal disease (ESRD) before age 30 years. Three age-based clinical subtypes are recognized: infantile, juvenile, and adolescent/adult.

- *Infantile NPH* can present in utero with oligohydramnios sequence (limb contractures, pulmonary hypoplasia and facial dysmorphisms) or postnatally with renal manifestations that progress to ESRD before age 3 years.
- *Juvenile NPH*, the most prevalent subtype, typically presents with polydipsia and polyuria, growth retardation, chronic iron-resistant anemia, or other findings related to chronic kidney disease (CKD). Hypertension is typically absent due to salt wasting. ESRD develops at a median age of 13 years. Ultrasound findings are increased echogenicity, reduced corticomedullary differentiation, and renal cysts (in 50% of affected individuals). Histologic findings include tubulointerstitial fibrosis, thickened and disrupted tubular basement membrane, sporadic corticomedullary cysts, and normal or reduced kidney size.
- *Adolescent/ adult NPH* is clinically similar to juvenile NPH, but ESRD develops at a median age of 19 years. Within a subtype inter- and intrafamilial variability in rate of progression to ESRD is considerable.

Approximately 80%-90% of individuals with the NPH phenotype have no extrarenal features (i.e., they have isolated NPH); ~10%-20% have extrarenal manifestations that comprise a recognizable syndrome (e.g., Joubert syndrome, Bardet-Biedl syndrome, Jeune syndrome and related skeletal disorders, Meckel-Gruber syndrome, Senior-Løken syndrome, Leber congenital amaurosis, COACH syndrome, and oculomotor apraxia, Cogan type).

**Diagnosis/testing.** Establishing the diagnosis of the NPH phenotype relies on presence of characteristic clinical findings and imaging findings on renal ultrasound examination.

Establishing the genetic cause of the NPH phenotype is possible in approximately 30%-40% of individuals by identification of homozygous or compound heterozygous deletions of *NPHP1* or biallelic pathogenic variants in one of the 19 known NPH-related genes.

**Genetic counseling.** Isolated and syndromic nephronophthisis are both inherited in an autosomal recessive manner. At conception, each sib of an affected individual has a 25% chance of being affected, a 50% chance of being an asymptomatic carrier, and a 25% chance of being unaffected and not a carrier. Heterozygotes (carriers) are asymptomatic and are not at risk of developing the disorder. Once the NPH-related pathogenic variants have been identified in an affected family member, prenatal testing or preimplantation genetic diagnosis for a pregnancy at increased risk for NPH may be options that a couple may wish to consider.

**Management.** *Treatment of manifestations:* Note: Treatment discussed in this *GeneReview* is limited to management of the NPH phenotype and does not include management of other findings observed in syndromic NPH. Treatment (based on international clinical practice) includes correction of water and electrolyte imbalances; treatment of anemia, hypertension, and proteinuria if present; growth hormone treatment in children who meet criteria for treatment; dialysis or renal transplantation for ESRD.

*Prevention of secondary complications:* Annual influenza vaccination for those with CKD; other vaccinations (e.g., pneumococcal vaccine and hepatitis B) according to local practice guidelines; standard measures to prevent secondary cardiovascular complications.

*Surveillance:* Monitoring of the following is recommended at least annually (and more frequently as needed for individuals with advanced CKD or at increased risk for disease progression and for therapeutic decision making): blood pressure, growth parameters, and psychomotor development; renal function; liver function; urinalysis (for evidence of proteinuria); abdominal ultrasound examination (for progression of renal disease and possible involvement of the liver, bile duct, spleen, and pancreas); and evaluations for extrarenal manifestations of syndromic NPH that can appear with time, especially retinal dystrophy.

*Agents/circumstances to avoid:* Nephrotoxic agents including nonsteroidal anti-inflammatory drugs (NSAIDs), aminoglycosides, and radiocontrast studies. For those with liver involvement: hepatotoxic medications.

*Evaluation of relatives at risk:* Presymptomatic diagnosis helps identify those who would benefit from prompt initiation of treatment and surveillance.

## **Clinical Description of the Nephronophthisis Phenotype**

---

Nephronophthisis is characterized by a reduced concentrating ability of the kidney, chronic tubulointerstitial nephritis, and progression to end-stage renal disease (ESRD) before age 30 years [Hildebrandt & Zhou 2007].

On average nephronophthisis is diagnosed 3.5 years after onset of symptoms as a result of the variable and nonspecific presentations [Soliman et al 2012].

The following three clinical subtypes (based on age of onset) are recognized. Of note, within a subtype, inter- and intrafamilial variability in rate of progression to ESRD can be considerable [Caridi et al 2006].

**Infantile nephronophthisis** can present in utero with an oligohydramnios sequence (limb contractures, pulmonary hypoplasia, and facial dysmorphisms) or with severe renal failure in the first years of life. Hypertension can be secondary to renal failure [Haider et al 1998, Otto et al 2003].

ESRD develops before age three years [Haider et al 1998, Otto et al 2003].

**Juvenile nephronophthisis**, the most prevalent form of nephronophthisis, typically presents with polydipsia and polyuria, growth retardation, or chronic iron-resistant anemia [Ala-Mello et al 1996, Hildebrandt et al 2009, Soliman et al 2012].

Other findings related to chronic kidney disease (CKD) may include metabolic bone disease, metabolic acidosis, uremic symptoms (e.g., nausea, anorexia and weakness), and proteinuria due to secondary glomerulosclerosis (late finding). Note that because of salt wasting, hypertension is typically absent [Hildebrandt et al 2009, Niaudet 2013].

ESRD develops at a median age of 13 years [Hildebrandt et al 1997, Hildebrandt et al 2009, Soliman et al 2012, Wolf 2015].

**Adolescent/ adult nephronophthisis.** Clinical features are similar to juvenile nephronophthisis. Note that the classification of adolescent/adult NPH is historically based on a single family with biallelic pathogenic variants in *NPHP3* in which ESRD developed at a median age of 19 years [Omran et al 2000, Olbrich et al 2003].

## Nomenclature

Nephronophthisis (literally ‘wasting of the nephrons’) is a renal ciliopathy. Ciliopathies are disorders of the primary cilium, a sensory organelle present on the apical surface of nearly all cell types, including renal tubular epithelial cells. Nephronophthisis (NPH) is considered a ciliopathy because the genes associated with NPH encode proteins that localize to the primary cilium (among other localizations such as cell-cell contacts; see [Molecular Genetic Pathogenesis](#)) [Fliegauf et al 2006, Omran 2010, Novarino et al 2011, Sang et al 2011, van Reeuwijk et al 2011]. Mutation of NPH-related genes often results in defects in cilia formation or ciliary protein trafficking [Bredrup et al 2011].

The term “nephronophthisis-related ciliopathies (NPHP-RC)” is used to describe isolated nephronophthisis, nephronophthisis with extrarenal features that do not constitute a recognizable syndrome, and syndromic nephronophthisis (see [Halbritter et al \[2013\]](#)).

## Prevalence

Juvenile nephronophthisis is the most prevalent form of nephronophthisis. The estimated incidence varies from 1:50,000 liveborns in Finland and Canada to 1:1,000,000 in the United States [Ala-Mello et al 1999, Waldherr et al 1982, Hildebrandt et al 2009]. The prevalence of nephronophthisis is likely underestimated as genetic testing in cohorts of adults with ESRD revealed individuals with undiagnosed nephronophthisis [Bollée et al 2006, Hoefele et al 2011].

Nephronophthisis, the most important monogenic cause of ESRD in children, is responsible for 2.4% to 15% of ESRD in this population [Hildebrandt et al 1993, Hamiwka et al 2008, Hildebrandt et al 2009].

## Establishing the Diagnosis of the Nephronophthisis Phenotype

The diagnosis of nephronophthisis phenotype is based on the following clinical findings, renal ultrasound findings, and family history.

### Clinical findings

- Polyuria and polydipsia resulting from a renal concentration defect
- Growth retardation
- Chronic anemia that is resistant to therapy
- Chronic renal failure:
  - Not resulting from congenital structural abnormalities of the kidneys and/or urinary tract
  - Without signs or symptoms of a glomerular cause

### Findings on renal ultrasound examination

- **Infantile NPH.** Moderately enlarged cystic kidneys with cortical hyperechogenicity [Gagnadoux et al 1989, Salomon et al 2009, Oud et al 2014]
- **Juvenile and adolescent NPH**

- Small to normal-sized kidneys [[Gagnadoux et al 1989](#), [Salomon et al 2009](#)]
- Increased echogenicity of the kidneys and reduced corticomedullary differentiation
- Renal cyst formation on the corticomedullary border in a later stage of the disease (~ 50% of individuals with juvenile nephronophthisis)
- In some cases, dilated bladder as a result of chronic polyuria (urinary tract is typically not dilated) [[Blowey et al 1996](#), [Hildebrandt et al 2009](#), [Chung et al 2014](#)]

**Family history.** Consistent with autosomal recessive inheritance

Note: While the characteristic histologic findings are tubulointerstitial fibrosis, thickened and disrupted tubular basement membrane, and sporadic corticomedullary cysts [[Zollinger et al 1980](#), [Hurd & Hildebrandt 2011](#), [Soliman et al 2012](#)], these are not required to make the diagnosis of nephronophthisis.

### Disorders Not Included in the NPH Phenotype

See [Table 1](#) for specific inherited disorders not included in the NPH phenotype.

In addition, conditions associated with a renal concentrating defect and growth retardation (e.g., nephrogenic diabetes insipidus and other tubulopathies) can mimic the NPH phenotype. For example, in 79 consanguineous and familial cases with childhood-onset CKD and NPH suspected on renal ultrasound examination, [Braun et al \[2016\]](#) identified pathogenic variants in NPH-related genes in 32 individuals and pathogenic variants in other monogenic kidney disease-associated genes in 18 individuals, including eight with a renal tubulopathy, four with Alport syndrome, three with a congenital anomaly of the kidney and urinary tract (CAKUT), two with autosomal recessive polycystic kidney disease (ARPKD), and one with autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED) syndrome (OMIM).

Biallelic pathogenic variants in *XPNPEP3* [[O'Toole et al 2010](#)] and in *SLC41A1* [[Hurd et al 2013](#)] can result in a nephronophthisis-like nephropathy.

### Table 1.

Disorders Not Included in the NPH Phenotype

[View in own window](#)

Disease Name	Gene(s)	MOI	Clinical Features	
			Overlapping	Distinguishing
<u>Autosomal dominant tubulointerstitial kidney disease, <i>MUC1</i>-related</u>	<i>MUC1</i>	AD	<ul style="list-style-type: none"> <li>Chronic tubulointerstitial kidney disease &amp; minimal or absent proteinuria</li> </ul>	<ul style="list-style-type: none"> <li>CKD is slow progressive leading to ESRD between 3<sup>rd</sup> &amp; 7<sup>th</sup> decade</li> <li>Hypertension, anemia, &amp; osteoporosis can occur secondary to renal insufficiency</li> </ul>
<u>Autosomal dominant tubulointerstitial kidney disease, <i>UMOD</i>-related</u>	<i>UMOD</i>	AD	<ul style="list-style-type: none"> <li>Chronic tubulointerstitial kidney disease</li> <li>Elevations in serum creatinine usually occur between ages 5 &amp; 10</li> </ul>	<ul style="list-style-type: none"> <li>Hyperuricemia &amp; gout usually occur as early as the teenage years<sup>3</sup></li> <li>ESRD usually occurs between 4<sup>th</sup> &amp; 7<sup>th</sup> decade<sup>3</sup></li> </ul>

MOI = mode of inheritance

AD = autosomal dominant

AR = autosomal recessive

CKD= chronic kidney disease

ESRD = end-stage renal disease

1. See *ADTKD-MUC1*.

2. See *ADTKD-UMOD*.

3. Scolari & Ghiggeri [2003], Bleyer & Hart [2009], *ADTKD-UMOD*. Mutation of *UMOD* causes glomerulocystic kidney disease with hyperuricemia and isosthenuria [Rampoldi et al 2003].

4. See *ADTKD-REN*.

5. Bingham et al [2001], Lennerz et al [2010], Kojima et al [2015]

6. Waters & Beales [2011]

## **Genetic Causes of the Nephronophthisis Phenotype**

The genetic cause of nephronophthisis (NPH) can be established by identifying biallelic pathogenic variants in one of the 19 known NPH-related genes (Table 2a and Table 2b). A genetic diagnosis can be established in approximately 30%-40% of individuals with the NPH phenotype using molecular genetic testing that includes sequence analysis and gene-targeted

deletion/duplication analysis [Otto et al 2010, Halbritter et al 2013].

Of note, additional genes associated with NPH-related ciliopathies are not currently classified as NPH-related genes in OMIM (e.g., *IFT140*, associated with skeletal ciliopathies with NPH and with isolated retinitis pigmentosa; *TRAF3IP1*, associated with Senior-Løken syndrome; and *IFT81*, associated with NPH and polydactyly) [Perrault et al 2012, Schmidts et al 2013, Bizet et al 2015, Perrault et al 2015, Xu et al 2015].

In addition, many more NPH-related genes have yet to be identified [Hildebrandt et al 2009, Otto et al 2011, Wolf & Hildebrandt 2011, Arts & Knoers 2013].

See Table 2a for the most common genetic causes of NPH (i.e., >1% of NPH) and Table 2b for less common genetic causes of NPH (i.e., <1% of NPH).

## Table 2a.

### Molecular Genetics of Nephronophthisis: Most Common Genetic Causes

Gene <sup>1,2</sup>	Locus	% of NPH Attributed to Pathogenic Variants in This Gene	Proportion of Pathogenic Variants <sup>3</sup> Detected by Test Method	
			Sequence analysis <sup>4</sup>	Gene-targeted deletion/duplication analysis <sup>5</sup>
<i>CEP290</i>	NPHP6	2%-3% <sup>6</sup>	2%-3% <sup>6</sup>	<1% <sup>7,8,9</sup>
<i>INVS</i>	NPHP2	1%-2% <sup>6</sup>	1%-2% <sup>6</sup>	Unknown <sup>7</sup>
<i>IQCB1</i>	NPHP5	2%-3% <sup>6</sup>	2%-3% <sup>6</sup>	Unknown <sup>7</sup>
<i>NPHP1</i>	NPHP1	20%-25% <sup>10</sup>	2%-3% <sup>11</sup>	20%-25% <sup>12</sup>
<i>NPHP3</i>	NPHP3	1%-2% <sup>13</sup>	1%-2% <sup>13</sup>	Unknown <sup>7</sup>
<i>NPHP4</i>	NPHP4	3%-4% <sup>13</sup>	3%-4% <sup>13</sup>	Unknown <sup>7</sup>
<i>TMEM67</i>	NPHP11	2%-3% <sup>6</sup>	2%-3% <sup>6</sup>	<1% <sup>7,14</sup>

Pathogenic variants of any one of the genes included in this table account for >1% of nephronophthisis.

1. Genes are listed in alphabetical order.
2. See Table A. Genes and Databases for chromosome locus and protein.
3. See Molecular Genetics for information on pathogenic allelic variants detected.
4. Sequence analysis detects variants that are benign, likely benign, of uncertain significance, likely pathogenic, or pathogenic. Pathogenic variants may include small intragenic deletions/insertions and missense, nonsense, and splice-site variants; typically, exon or whole-gene deletions/duplications are not detected. For issues to consider in interpretation of sequence analysis results, click here.
5. Gene-targeted deletion/duplication analysis detects intragenic deletions or duplications. Methods that may be used include: quantitative PCR, long-range PCR, multiplex ligation-dependent probe amplification (MLPA), and a gene-targeted microarray designed to detect single-exon deletions or duplications.
6. Tory et al [2009], Halbritter et al [2013], Braun et al [2016]
7. No data on detection rate of gene-targeted deletion/duplication analysis are available.
8. A heterozygous multi-exon deletion was detected in 1 of 9 individuals with a ciliopathy and a *CEP290* heterozygous pathogenic variant [Travaglini et al 2009].

9. A heterozygous 1.9-Mb deletion that included *CEP290* and a *CEP290* nonsense pathogenic variant were identified in a fetus with Meckel-Gruber syndrome [Molin et al 2013].
10. Hildebrandt et al [2009], Halbritter et al [2013]
11. Two of 79 persons with suspected NPH [Braun et al 2016]; 11 of 470 persons (5 of whom were heterozygous) [Otto et al 2008]
12. 97 of 470 persons with NPH were homozygous for the common *NPHP1* deletion (see Molecular Genetics) [Otto et al 2008, Braun et al 2016].
13. Otto et al [2008], Halbritter et al [2013], Braun et al [2016]
14. A homozygous *TMEM67* intragenic deletion was identified in 1 of 120 individuals with Meckel-Gruber syndrome [Khaddour et al [2007].

**Table 2b.**

Molecular Genetics of Nephronophthisis: Less Common Genetic Causes

Gene <sup>1, 2</sup>	Locus	Comment <sup>3</sup>
<i>ANKS6</i>	NPHP16	<ul style="list-style-type: none"> <li>• Pathogenic variants detected in 5 families w/infantile NPH &amp; 1 family w/juvenile NPH<sup>4</sup></li> <li>• Homozygosity for a pathogenic variant identified in a Turkish family w/NPH; heterozygosity for 4 variants found in 56 additional patients<sup>5</sup></li> </ul>
<i>CEP83</i>	NPHP18	<ul style="list-style-type: none"> <li>• Homozygous or compound heterozygous pathogenic variants identified in 8 of 1,255 individuals w/NPH-related ciliopathies</li> <li>• Early-onset NPH associated w/intellectual disability and/or hydrocephalus in 4 patients<sup>6</sup></li> </ul>
<i>CEP164</i>	NPHP15	<ul style="list-style-type: none"> <li>• A homozygous missense pathogenic variant identified in a Saudi child w/NPH and Leber <u>congenital amaurosis</u><sup>7</sup></li> <li>• Biallelic pathogenic variants identified in 3 of 856 families w/NPH-related ciliopathies. Phenotypes ranged from severe retinal dystrophy (inactivating variants) to Senior-Løken syndrome &amp; <u>isolated</u> NPH (hypomorphic variants).<sup>7</sup></li> </ul>
<i>DCDC2</i>	NPHP19	<ul style="list-style-type: none"> <li>• Biallelic truncating pathogenic variants identified in 2 unrelated individuals w/NPH and early-onset severe hepatic fibrosis<sup>8</sup></li> </ul>
<i>GLIS2</i>	NPHP7	<ul style="list-style-type: none"> <li>• Homozygous pathogenic variants identified in 3 affected members of a Canadian Oji-Cree family &amp; 1 Turkish patient w/<u>isolated</u> NPH<sup>9</sup></li> </ul>
		<ul style="list-style-type: none"> <li>• Biallelic pathogenic variants identified in 12 families w/short-rib thoracic dysplasia &amp; NPH &amp; in 4 families w/retinitis pigmentosa-associated ciliopathies<sup>10</sup></li> </ul>

<i>IFT172</i>	NPHP17	<ul style="list-style-type: none"> <li>• Compound heterozygous variants found in 2 persons w/Jeune asphyxiating thoracic dystrophy &amp; Mainzer-Saldino syndrome including renal features; &amp; in 1 person w/renal, skeletal, &amp; ophthalmologic findings as well as pituitary hypoplasia &amp; an ectopic posterior pituitary gland <sup>11</sup></li> </ul>
<i>NEK8</i>	NPHP9	<ul style="list-style-type: none"> <li>• Homozygous missense pathogenic variants identified in a Kurdish child who had ESRD by age 3 years</li> <li>• Homozygous nonsense pathogenic variants identified in a family w/a severe embryonic ciliopathy, including cystic enlargement of the kidneys <sup>12</sup></li> </ul>
<i>RPGRIP1L</i>	NPHP8	<ul style="list-style-type: none"> <li>• Pathogenic variants cause Joubert syndrome. Biallelic truncating variants generally cause the more severe Meckel-Gruber syndrome. <sup>13</sup></li> </ul>
<i>SDCCAG8</i>	NPHP10	<ul style="list-style-type: none"> <li>• Biallelic pathogenic variants found in 12 families w/NPH &amp; retinal degeneration (Senior-Løken syndrome &amp; Bardet-Biedl syndrome) <sup>14</sup></li> <li>• Homozygous deletions of exons 5 to 7 have been described. <sup>15</sup></li> </ul>
<i>TTC21B</i>	NPHP12	<ul style="list-style-type: none"> <li>• Biallelic pathogenic variants detected in 7 families w/NPH w/ or w/out extrarenal features, 3 families w/Jeune asphyxiating thoracic dystrophy, &amp; additional families w/a NPH-related ciliopathy <sup>16</sup></li> <li>• Biallelic missense variants also identified in persons w/familial primary focal segmental glomerulosclerosis [<u>Huynh Cong et al 2014</u>, <u>Bullich et al 2016</u>] <sup>16</sup></li> <li>• 2 families had infantile NPH w/extrarenal features. <sup>17</sup></li> </ul>
<i>WDR19</i>	NPHP13	<ul style="list-style-type: none"> <li>• Biallelic pathogenic variants identified in families w/cranioectodermal dysplasia, Jeune syndrome, Senior-Løken syndrome, &amp; <u>isolated</u> NPH <sup>18</sup></li> <li>• 8 individuals w/biallelic pathogenic variants had NPH &amp; dilation of the intrahepatic bile ducts. <sup>19</sup></li> </ul>
<i>ZNF423</i>	NPHP14	<ul style="list-style-type: none"> <li>• Homozygosity for a missense pathogenic variant identified in Turkish sibs w/infantile NPH, cerebellar vermis hypoplasia, &amp; situs inversus <sup>7</sup></li> <li>• Heterozygous pathogenic variants present in 2 individuals w/Joubert syndrome demonstrated (in cellular studies) a <u>dominant negative</u> effect on protein function. <sup>7</sup></li> </ul>



Biallelic pathogenic variants in any one of the genes listed in this table are reported in only a few families (i.e., <1%) with nephronophthisis).

1. Genes are listed in alphabetic order.
2. See [Table A. Genes and Databases](#) for [chromosome locus](#) and protein.
3. Only sequence variants have been reported thus far in all listed genes, with the exception of *SDCCAG8*, in which deletions associated with nephronophthisis have been reported.
4. [Hoff et al \[2013\]](#)
5. [Taskiran et al \[2014\]](#)
6. [Failler et al \[2014\]](#)
7. [Chaki et al \[2012\]](#)
8. [Schueler et al \[2015\]](#)
9. [Attanasio et al \[2007\]](#), [Halbritter et al \[2013\]](#)
10. [Halbritter et al \[2013\]](#), [Bujakowska et al \[2015\]](#)
11. [Lucas-Herald et al \[2015\]](#), [McInerney-Leo et al \[2015\]](#)
12. [Otto et al \[2008\]](#), [\[Frank et al 2013\]](#)
13. [Arts et al \[2007\]](#), [Delous et al \[2007\]](#), [Wolf et al \[2007\]](#), [Brancati et al \[2008\]](#), [Otto et al \[2011\]](#), [Kroes et al \[2016\]](#)
14. [Otto et al \[2010\]](#), [Schaefer et al \[2011\]](#), [Billingsley et al \[2012\]](#)
15. [Otto et al \[2010\]](#), [Chaki et al \[2011\]](#), [Schaefer et al \[2011\]](#)
16. [Davis et al \[2011\]](#), [Halbritter et al \[2013\]](#), [Huynh Cong et al \[2014\]](#), [McInerney-Leo et al \[2015\]](#)
17. [Otto et al \[2011\]](#)
18. [Bredrup et al \[2011\]](#), [Coussa et al \[2013\]](#), [Halbritter et al \[2013\]](#)
19. [Halbritter et al \[2013\]](#), [Lee et al \[2015\]](#)

### **Isolated Nephronophthisis vs Syndromic Nephronophthisis**

Approximately 80%-90% of individuals with nephronophthisis have no extrarenal features (i.e., they have isolated nephronophthisis); the remaining 10%-20% of individuals with nephronophthisis have extrarenal manifestations that can comprise a recognizable syndrome [[Hildebrandt et al 2009](#), [Wolf 2015](#)]. NPH-related genes and their associated phenotypes are summarized ([Table 3a](#) and [Table 3b](#)).

#### **Table 3a.**

Phenotypes of Syndromic Nephronophthisis

[View in own window](#)

Disorder <sup>1</sup>	Major Distinguishing Clinical Features <sup>2</sup>						
	Cerebellar <sup>3</sup>	ID <sup>4</sup>	Eye <sup>5</sup>	Skeletal dysplasia <sup>6</sup>	Polydactyly <sup>7</sup>	Hepatic fibrosis	SI
<u>Joubert syndrome</u>	+	+	+		+	+	-
<u>Bardet-Biedl syndrome</u>	+	+	+		+	+	-
Jeune syndrome and related skeletal disorders <sup>8</sup>		+	+	+	+	+	
<u>Meckel-Gruber syndrome</u> <sup>9</sup>				+	+	+	-
<u>Senior-Løken syndrome</u>			+			+	-
Leber							

ID = intellectual disability

SI = situs inversus

COACH = cerebellar vermis hypoplasia, oligophrenia, ataxia, coloboma, and hepatic fibrosis

1. Although all syndromes listed here are associated with NPH, the prevalence of renal disease varies. Renal disease (including nephronophthisis) has been reported in: 23%-30% of individuals with Joubert syndrome [Doherty 2009, Kroes et al 2016]; 53%-82% of individuals with Bardet-Biedl syndrome [Imhoff et al 2011, Forsythe & Beales 2013]; 21% of families and 33% of individuals with COACH syndrome [Brancati et al 2008, Doherty et al 2010]; and 19 of 31 individuals with Jeune syndrome (see Cranioectodermal Dysplasia). Nephronophthisis is an obligatory finding in Senior-Løken syndrome. The prevalence of renal disease is unknown for the other NPH-related syndromes.
2. Based on Gerdes et al [2009], Simms et al [2011], Waters & Beales [2011], Arts & Knoers [2013].
3. Cerebellar findings include molar tooth sign in Joubert syndrome, cerebellar vermis hypoplasia and ataxia in Joubert syndrome and COACH syndrome, ataxia or poor coordination in Bardet-Biedl syndrome, and oculomotor apraxia in Joubert syndrome and oculomotor apraxia, Cogan type [Forsythe & Beales 2013].
4. Cognitive ability ranges from normal to severe disability. Individuals with Jeune syndrome and related skeletal disorders usually have normal cognitive abilities; those with Joubert syndrome and COACH syndrome frequently have some degree of cognitive impairment [Arts & Knoers 2013].
5. Ophthalmologic features include retinitis pigmentosa in Joubert syndrome, Bardet-Biedl syndrome, cranioectodermal dysplasia (CED), Senior-Løken syndrome, and Leber congenital amaurosis; coloboma in Joubert syndrome; and oculomotor apraxia in Joubert syndrome and oculomotor apraxia, Cogan type

[Waters & Beales 2011].

6. Skeletal findings include rhizomelic limb shortening, brachydactyly, and narrow thorax in Jeune syndrome and CED. Narrow thorax is more severe and often lethal in Jeune syndrome [Arts & Knoers 2013]. Skeletal findings in Meckel-Gruber syndrome comprise bowing of long bones, malformations of the cranial base, and vertebral clefting [Kjaer et al 1999].
7. Polydactyly is usually postaxial; however, other forms have been described. See [Joubert Syndrome and Related Disorders](#).
8. Includes cranioectodermal dysplasia (CED) characterized by craniosynostosis and ectodermal involvement
9. Meckel-Gruber syndrome is a perinatally lethal ciliopathy that is associated with enlarged cystic kidneys (i.e., infantile nephronophthisis) [Wolf 2015].

**Table 3b.**

NPH-Related Genes Associated with Syndromic Nephronophthisis

[View in own window](#)

Disorder	NPH-Related Genes <sup>1</sup>						
	<i>NPHP1</i> <sup>2</sup>	<i>NPHP3</i>	<i>NPHP4</i>	<i>CEP290</i>	<i>RPGRI1L</i>	<i>TMEM67</i>	<i>T</i>
Joubert syndrome <sup>3</sup>	1%-2%	+	+	10%	2%-4%	10%	+
Bardet-Biedl syndrome <sup>4</sup>				+		+	
Jeune syndrome & related skeletal disorders <sup>5</sup>							+
Meckel-Gruber syndrome <sup>6</sup>		+		+	+	+	
Senior-Løken syndrome <sup>7</sup>	+	+	+	+			
Leber congenital amaurosis <sup>8</sup>				20%			
COACH syndrome <sup>9</sup>					4%-5%	74%	

Associated genes based on [OMIM](#)

+ indicates that mutation of the gene accounts for some (unknown percentage) of the disorder. Percentages are provided where known.

1. Betz et al [2000], Gerdes et al [2009], Hildebrandt et al [2009], Simms et al [2011], Waters & Beales [2011], Arts & Knoers [2013]



attention to sibs who may have nephronophthisis or one of the syndromic forms of nephronophthisis (Table 3a).

**Genomic/genetic testing to confirm the molecular diagnosis of NPHP** is outlined in Figure 1. Recent studies indicate that molecular testing (use of single-gene testing and/or multi-gene panel) can identify biallelic pathogenic variants in one of the 19 known NPH-related genes in approximately 30%-40% of affected individuals [Otto et al 2010, Halbritter et al 2013, Braun et al 2016].

1. Testing for all persons with nephronophthisis (whether nonsyndromic or syndromic) begins with ***NPHP1* gene-targeted deletion/duplication analysis**, as deletions in *NPHP1* are detected in 20%-25% of individuals with isolated (i.e., nonsyndromic) nephronophthisis [Hildebrandt et al 2009, Halbritter et al 2013].
2. **If only one allele** is determined to have an *NPHP1* deletion, follow gene-targeted deletion/duplication analysis with ***NPHP1* sequence analysis** [Otto et al 2008].
  - a. If sequence analysis does not identify a pathogenic variant on the other allele, a **multi-gene panel** (3.a.) and/or **more comprehensive genomic testing** (3.b.) including whole-exome sequencing (WES) or whole-genome sequencing (WGS) can also be considered, as the individual may be a carrier of a heterozygous variant in *NPHP1* with disease caused by biallelic pathogenic variants in another NPH-related gene.
3. **If neither allele** has an *NPHP1* deletion identified on gene-targeted deletion/duplication analysis, proceed to use of a **multi-gene panel** (3.a.) and/or **more comprehensive genomic testing** (3.b.) including WES or WGS to determine if biallelic pathogenic variants can be identified in another NPH-related gene [Braun et al 2016].
  - a. The multi-gene panel should include the 19 NPH-related genes and other ciliopathy or renal disease-related genes of interest [Perrault et al 2012, Halbritter et al 2013, Failler et al 2014]. (For an overview of ciliopathy genes, see Braun et al [2016] or Schueler et al [2016].)  
Note: The genes included in the panel and the diagnostic sensitivity of the testing used for each gene vary by laboratory and over time.
  - b. If use of a multi-gene panel fails to confirm a diagnosis in an individual with features of NPH (or if use of a multi-gene panel is not an available or preferred next step), more comprehensive genomic testing (when available) including WES and WGS may be considered. For issues to consider in interpretation of genomic test results, click [here](#).

## Genetic Counseling

---

*Genetic counseling is the process of providing individuals and families with information on the nature, inheritance, and implications of genetic disorders to help them make informed medical and personal decisions. The following section deals with genetic risk assessment and the use of family history and genetic testing to clarify genetic status for family members. This section is not meant to address all personal, cultural, or ethical issues that individuals may face or to substitute for consultation with a genetics professional. —ED.*

## Mode of Inheritance

Nephronophthisis is inherited in an autosomal recessive manner.

## Risk to Family Members

## Parents of a proband

- The parents of an affected child are obligate heterozygotes (i.e., carriers of one NPH-related pathogenic variant).
- Heterozygotes (carriers) are asymptomatic and are not at risk of developing the disorder.

## Sibs of a proband

- At conception, each sib of an affected individual has a 25% chance of being affected, a 50% chance of being an asymptomatic carrier, and a 25% chance of being unaffected and not a carrier.
- Heterozygotes (carriers) are asymptomatic and are not at risk of developing the disorder.

**Offspring of a proband.** The offspring of an individual with nephronophthisis are obligate heterozygotes (carriers) for a nephronophthisis-related pathogenic variant.

**Other family members.** Each sib of the proband's parents is at a 50% risk of being a carrier of a nephronophthisis-related pathogenic variant.

## Related Genetic Counseling Issues

See Management, Evaluation of Relatives at Risk for information on evaluating at-risk relatives for the purpose of early diagnosis and treatment.

**DNA banking** is the storage of DNA (typically extracted from white blood cells) for possible future use. Because it is likely that testing methodology and our understanding of genes, allelic variants, and diseases will improve in the future, consideration should be given to banking DNA of affected individuals.

## Prenatal Testing and Preimplantation Genetic Diagnosis

Once the nephronophthisis-related pathogenic variants have been identified in an affected family member, prenatal testing and preimplantation genetic diagnosis for a pregnancy at increased risk for nephronophthisis are possible options.

Differences in perspective may exist among medical professionals and within families regarding the use of prenatal testing, particularly if the testing is being considered for the purpose of pregnancy termination rather than early diagnosis. Although most centers would consider decisions about prenatal testing to be the choice of the parents, discussion of these issues is appropriate.

## Resources

---

*GeneReviews staff has selected the following disease-specific and/or umbrella support organizations and/or registries for the benefit of individuals with this disorder and their families. GeneReviews is not responsible for the information provided by other organizations. For information on selection criteria, click [here](#).*

- **National Library of Medicine Genetics Home Reference**  
[Nephronophthisis](#)
- **American Kidney Fund**  
11921 Rockville Pike  
Suite 300  
Rockville MD 20852  
**Phone:** 866-300-2900

**Email:** [helpline@kidneyfund.org](mailto:helpline@kidneyfund.org)  
[www.kidneyfund.org](http://www.kidneyfund.org)

- **Ciliopathy Alliance**

United Kingdom

**Phone:** 44 20 7387 0543

[www.ciliopathyalliance.org](http://www.ciliopathyalliance.org)

- **Kidney Foundation of Canada**

310-5160 Decarie Blvd.

Montreal Ontario H3X 2H9

Canada

**Phone:** 800-361-7494 (toll-free); 514-369-4806

**Fax:** 514-369-2472

**Email:** [info@kidney.ca](mailto:info@kidney.ca)

[www.kidney.ca](http://www.kidney.ca)

- **National Kidney Foundation (NKF)**

30 East 33rd Street

New York NY 10016

**Phone:** 800-622-9010 (toll-free); 212-889-2210

**Email:** [info@kidney.org](mailto:info@kidney.org)

[www.kidney.org](http://www.kidney.org)

- **NephCure Kidney International**

15 Waterloo Avenue

Berwyn PA 19312

**Phone:** 866-NephCure; 866-637-4287

**Email:** [info@nephcure.org](mailto:info@nephcure.org)

[nephcure.org](http://nephcure.org)

## Management

---

### Evaluations Following Initial Diagnosis

To establish the extent of disease and needs in an individual diagnosed with nephronophthisis, the following evaluations are recommended [Parisi et al 2007, Simms et al 2011, KDIGO 2013]:

- Detailed family history and physical examination including blood pressure, growth parameters, developmental assessment, and dysmorphology examination to evaluate for extrarenal manifestations (Table 3a)
- Tests to evaluate the kidneys:
  - Tests of renal function including serum creatinine concentration, estimated glomerular filtration rate (eGFR), urea or blood urea nitrogen (BUN), and electrolytes
  - Complete blood count (CBC) to evaluate for anemia
  - Tests to evaluate for the metabolic bone disease of chronic kidney disease (CKD) including serum calcium, phosphate, parathyroid hormone (PTH), and alkaline phosphatase activity
  - Urinalysis from first-morning void for specific gravity to test concentrating ability (if feasible), proteinuria

- Tests of liver function including serum concentrations of transaminases, albumin, bilirubin, and prothrombin time
- Abdominal ultrasound examination to evaluate renal findings consistent with nephronophthisis and to evaluate for additional anomalies in liver, bile duct, spleen, and/or pancreas (including situs inversus)
- Referral as needed for evaluation of extrarenal manifestations, including:
  - Ophthalmologic examination
  - Brain MRI
  - Skeletal radiographs
  - Assessment of psychomotor development and/or behavior
  - Neurologic assessment
  - Endocrine assessment
  - Cardiac ultrasound examination
- Consultation with a clinical geneticist and/or genetic counselor

## Treatment of Manifestations

This section discusses only the management of the phenotype of nephronophthisis. Management of other findings associated with syndromic NPH (Table 3a) are beyond the scope of this *GeneReview*.

Currently no cure for nephronophthisis exists. Treatment is aimed at slowing the progression of CKD and its complications, according to international clinical practice guidelines for chronic renal failure (Kidney Disease – Improving Global Outcomes [KDIGO] 2012 Clinical Practice Guideline (CPG) for Evaluation and Management of Chronic Kidney Disease [KDIGO 2013] (full text):

- Correction of water and electrolyte imbalances, especially during intercurrent illness
- Treatment of anemia, hypertension, and proteinuria if present. Preferred therapy may differ between adult and pediatric patients [KDIGO 2013].
- Growth hormone treatment for children who have severe growth retardation as a result of chronic renal insufficiency and meet criteria for treatment [Wilson et al 2003]
- Dialysis or renal transplantation when patients reach ESRD. Renal transplantation is the preferred treatment as disease does not recur in the transplanted kidney [Pistor et al 1985].

## Prevention of Secondary Complications

Annual influenza vaccination is indicated for patients with CKD. Other vaccinations (e.g., pneumococcal vaccine and hepatitis B) should follow local practice guidelines [KDIGO 2013].

For measures to prevent secondary cardiovascular complications, see KDIGO Clinical Practice Guideline for Evaluation and Management of Chronic Kidney Disease [KDIGO 2013] (full text).

## Surveillance

Evaluations are recommended at least annually. More frequent monitoring is recommended for



individuals with advanced-stage CKD, individuals at higher risk of disease progression, or when assessment will affect therapeutic decision making [[KDIGO 2013](#)].

- Monitoring of blood pressure, growth parameters, and development
- Renal function including serum creatinine concentration and estimated glomerular filtration rate (eGFR), urea or BUN, electrolytes, CBC, CKD metabolic bone disease including serum calcium, phosphate, PTH and alkaline phosphatase activity
- Liver function including serum concentrations of transaminases, albumin, bilirubin and prothrombin time
- Urinalysis to monitor proteinuria
- Abdominal ultrasound examination to evaluate progression of renal disease and possible liver, bile duct, spleen or pancreas anomalies
- Routine evaluations for extrarenal manifestations of syndromic NPH that can appear with time, especially ophthalmologic examination for visual acuity, visual field examination, and evidence of retinal dystrophy

### **Agents/Circumstances to Avoid**

Nephrotoxic agents, e.g., nonsteroidal anti-inflammatory drugs (NSAIDs), aminoglycosides, and radiocontrast studies should be avoided.

Individuals with liver function impairment should avoid hepatotoxic medication.

### **Evaluation of Relatives at Risk**

It is appropriate to evaluate apparently asymptomatic older and younger sibs of a proband with NPH in order to identify as early as possible those who would benefit from initiation of treatment and surveillance measures.

Evaluations can include:

- Molecular genetic testing if the NPH-related pathogenic variants in the family are known;
- Monitoring of renal function and blood pressure if the pathogenic variants in the family are not known.

See Genetic Counseling for issues related to testing of at-risk relatives for genetic counseling purposes.

### **Pregnancy Management**

For reviews of management of CKD in pregnancy see Smyth et al [2013] and Piccoli et al [2015].

### **Therapies Under Investigation**

Search ClinicalTrials.gov for access to information on clinical studies for a wide range of diseases and conditions.

## **Molecular Genetics**

---

### **Molecular Genetic Pathogenesis**

Almost all nephronophthisis-related genes (NPH-related genes) encode proteins localized to the

cilium at the ciliary transition zone, the inversin compartment, or subunits of the IFT complexes where they are involved in ciliogenesis and regulation of ciliary protein trafficking [Fliegauf et al 2006, Omran 2010, Novarino et al 2011, Sang et al 2011, van Reeuwijk et al 2011]. In addition, the protein products of *NPHP1*, *INVS*, and *NPHP4* localize to and regulate cell-cell junctions [Donaldson et al 2002, Delous et al 2009, Hurd & Hildebrandt 2011].

The mechanism by which disruption in these NPH-related proteins leads to nephronophthisis is unknown, although recent studies have shed light on nephrocystin functions and associated pathways. Nephrocystins are implicated in important signaling pathways, such as the Wnt pathway (involved in apical-basolateral polarity of renal tubular cells in response to tubular flow) [Simons et al 2005], the Hedgehog pathway (involved in mesenchymal-to-epithelial transition in renal tubulogenesis) [Yu et al 2002, Attanasio et al 2007], and the Hippo pathway (involved in regulation of tissue growth) [Benzing & Schermer 2012, Barker et al 2014, Wolf 2015].

In addition, the NPH-related genes *NEK8*, *CEP164*, *SDCCAG8*, *CEP290* and *ZNF423* play a dual role in the nucleus and have been implicated in DNA damage response (DDR) signaling [Chaki et al 2012, Zalli et al 2012, Choi et al 2013, Yuan & Sun 2013, Airik et al 2014, Slaats et al 2014, Slaats & Giles 2015, Slaats et al 2015]. As pathogenic variants in *CEP164* induce epithelial-to-mesenchymal transition and a profibrotic response [Slaats et al 2014], the DDR pathway may be most closely linked to tubulointerstitial fibrosis, a hallmark feature of nephronophthisis [Slaats & Giles 2015].

Cilia are present on nearly all cell types, and pathogenic variants in NPH-related genes affect cilia function in a tissue-specific manner [Garcia-Gonzalo et al 2011, Benzing & Schermer 2012], accounting for the wide variety of extrarenal manifestations in nephronophthisis-related ciliopathies.

The considerable inter- and intrafamilial variability in the associated extrarenal manifestations and the rate of progression to ESRD may be due to the degree of protein impairment and the contribution of genetic modifiers [Caridi et al 2006, Hoefele et al 2007, Littink et al 2010, Drivas et al 2015]. Oligogenic inheritance has been described in several NPH-related ciliopathies [Katsanis et al 2001, Badano et al 2003, Baala et al 2007b, Helou et al 2007, Tory et al 2007, Leitch et al 2008, Louie et al 2010, Davis et al 2011, Lin et al 2013, Zhang et al 2014]. Note that some proposed modifier alleles occur frequently in control populations and, therefore, their own pathogenicity is debatable (e.g., see, the ExAC Browser).

Examples of proposed genetic modifiers for NPH-related genes include the following:

- An *NPHP1* pathogenic variant as a modifier of an NPH-related ciliopathy phenotype, such as Bardet-Biedl syndrome [Lindstrand et al 2014]
- A heterozygous truncating variant in *CEP290* in one person and heterozygous missense variants in *AHII* in six persons with homozygous *NPHP1* deletions [Tory et al 2007]. Variants in *CEP290* and *AHII* were hypothesized to contribute to neurologic findings in these seven individuals who had biallelic *NPHP1* pathogenic variants.
- An enrichment of pathogenic variants in *TTC21B* in individuals with a ciliopathy, suggesting a modifier role for *TTC21B* [Davis et al 2011].

Note: To date no heterozygous *NPHP1* pathogenic variant has been identified as a modifier in isolated nephronophthisis caused by biallelic pathogenic variants in another NPH-related gene.

## ***NPHP1***

**Gene structure.** *NPHP1* comprises 20 exons and is alternatively spliced in 11 variants. The largest transcript is NM\_000272. It encodes a 732-amino acid product. *NPHP1* is flanked by

segmental duplications that are prone to non-allelic homologous recombination [Saunier et al 2000]. For a detailed summary of gene and protein information, see [Table A, Gene](#).

**Benign allelic variants.** Saunier et al [2000] demonstrated a benign rearrangement involving the two 330-kb inverted repeats surrounding the common 290-kb deletion in homozygous state in two controls (1.3%).

*NPHP1* duplications have been described in persons with autism spectrum disorders and developmental delay without associated renal features [Baris et al 2006, Yasuda et al 2014].

**Pathogenic allelic variants.** The common *NPHP1* 290-kb deletion (which includes the entire gene) is found in the homozygous state in 20%-25% of persons with nephronophthisis [Hildebrandt et al 2009, Halbritter et al 2013].

Other loss-of-function pathogenic variants, such as p.Leu27Ter, occur in the compound heterozygous state with the common deletion in individuals with NPH [Saunier et al 1997, Hildebrandt et al 1997].

**Modifier allelic variants.** It has been proposed that heterozygous pathogenic variants act as modifier alleles in Bardet-Biedl syndrome [Lindstrand et al 2014].

#### Table 4.

*NPHP1* Pathogenic Variants Discussed in This GeneReview

DNA Nucleotide Change	Predicted Protein Change	Reference Sequences
290-kb deletion including entire gene		<a href="#">NM_000272</a> <a href="#">NP_000263</a>
c.80T>A	p.Leu27Ter	<a href="#">NM_000272.3</a> <a href="#">NP_000263.2</a>

Note on variant classification: Variants listed in the table have been provided by the authors. *GeneReviews* staff have not independently verified the classification of variants.

Note on nomenclature: *GeneReviews* follows the standard naming conventions of the Human Genome Variation Society ([www.hgvs.org](http://www.hgvs.org)). See [Quick Reference](#) for an explanation of nomenclature.

**Normal gene product.** *NPHP1* encodes nephrocystin 1, which localizes to the ciliary transition zone. The C-terminal region mediates *NPHP1* localization to cell-cell junctions, interaction with filamins, establishment of cell polarity, and interaction of with *NPHP4* [Donaldson et al 2002, Mollet et al 2005].

**Abnormal gene product.** Loss of *NPHP1* function causes disease. For information on animal models click [here](#).

#### *INVS (NPHP2)*

**Gene structure.** *INVS* comprises 17 exons. It has eight transcripts of which the longest is [NM\\_014425](#). For a detailed summary of gene and protein information, see [Table A, Gene](#).

**Pathogenic allelic variants.** Biallelic truncating and missense pathogenic variants cause infantile and juvenile NPH [Gagnadoux et al 1989, Otto et al 2003, Tory et al 2009, Chaki et al 2011, Halbritter et al 2013].

Two individuals with compound heterozygous *INVS* truncating pathogenic variants had isolated juvenile-onset NPH (c.1417delG, c.3125delA, c.2695C>T, c.2782C>T) [Halbritter et al 2013].

There was no clear correlation between the type of pathogenic variant and the presence or severity of situs inversus or other extrarenal ophthalmologic, central nervous system, and cardiac features [Otto et al 2003, O'Toole et al 2006, Otto et al 2008, Tory et al 2009, Chaki et al 2011].

### Table 5.

*INVS* Pathogenic Variants Discussed in This *GeneReview*

DNA Nucleotide Change	Predicted Protein Change	Reference Sequences
c.1417delG	p.Ala473GlnfsTer37	<a href="#">NM_014425.3</a>
c.3125delA	p.Asn1042ThrfsTer64	<a href="#">NM_014425.3</a>
c.2695C>T	p.Arg899Ter	<a href="#">NM_014425.3</a> <a href="#">NP_055240.2</a>
c.2782C>T	p.Arg928Ter	<a href="#">NM_014425.3</a> <a href="#">NP_055240.2</a>

Note on variant classification: Variants listed in the table have been provided by the authors. *GeneReviews* staff have not independently verified the classification of variants.

Note on nomenclature: *GeneReviews* follows the standard naming conventions of the Human Genome Variation Society ([www.hgvs.org](http://www.hgvs.org)). See [Quick Reference](#) for an explanation of nomenclature.

**Normal gene product.** *INVS* encodes a 1065-amino acid protein. *INVS* contains several domains and protein-binding motifs, including 16 ankyrin repeats, two IQ domains (including 1 calmodulin-binding domain), two D boxes (including 1 anaphase-promoting complex subunit-2 [APC2]-binding D box), and a bipartite nuclear localization signal (NLS-BP) [Morgan et al 2002a, Morgan et al 2002b, Schön et al 2002, Otto et al 2003]. *INVS* localizes to and defines the *INVS* compartment.

*INVS*:

- Interacts with a C-terminal region of NPHP1 [Otto et al 2003];
- Interacts with catenins and N-cadherin at membrane regions of cell-cell contact [Nürnberg et al 2002];
- Interacts in a complex with NEK8, NPHP3, and ANKS6 [Hoff et al 2013];
- Is involved in regulation of ciliary disassembly through phosphorylation and inhibition of Aurora A, a cell cycle kinase that promotes ciliary disassembly [Mergen et al 2013];
- Plays a role in the Wnt pathway [Simons et al 2005].

**Abnormal gene product.** See [Animal Models](#).

### ***NPHP3***

**Gene structure.** *NPHP3* comprises 27 exons. It has 14 different transcripts. The longest transcript, [NM\\_153240](#), encodes a protein of 1330 amino acids. For a detailed summary of gene and protein information, see [Table A, Gene](#).

**Pathogenic allelic variants.** Homozygous pathogenic variants in *NPHP3* cause infantile-onset, juvenile-onset, and adolescent-onset NPH [Olbrich et al 2003, Simpson et al 2009, Tory et al 2009, Halbritter et al 2013].

The homozygous nonsense pathogenic variant p.Arg702Ter was identified in 12 infants from six

Amish families with neonatal lethal NPH [Simpson et al 2009].

*NPHP3* pathogenic variants were identified in children with infantile-onset NPH [Simpson et al 2009, Tory et al 2009, Halbritter et al 2013] and in two families with Meckel-Gruber syndrome [Bergmann et al 2008, Tory et al 2009].

Homozygous in-frame deletion of three base pairs in *NPHP3* (p.Gly1275del) was first detected in a Venezuelan family with adolescent-onset NPH [Olbrich et al 2003].

Brain and cardiac anomalies have been associated with biallelic nonsense pathogenic variants [Chaki et al 2011]. Liver fibrosis is a common extrarenal feature [Tory et al 2009, Halbritter et al 2013].

## Table 6.

### *NPHP3* Pathogenic Variants Discussed in This *GeneReview*

DNA Nucleotide Change	Predicted Protein Change	Reference Sequences
c.2104C>T	p.Arg702Ter	NM_153240.4 NP_694972.3
c.3824_3826delGAG	p.Gly1275del	

Note on variant classification: Variants listed in the table have been provided by the authors. *GeneReviews* staff have not independently verified the classification of variants.

Note on nomenclature: *GeneReviews* follows the standard naming conventions of the Human Genome Variation Society ([www.hgvs.org](http://www.hgvs.org)). See [Quick Reference](#) for an explanation of nomenclature.

**Normal gene product.** The longest *NPHP3* transcript encodes a protein of 1330 amino acids.

*NPHP3*:

- Contains a coiled coil domain, a tubulin-tyrosine ligase domain, and a tetratricopeptide repeat (TPR) domain which is predicted at the site of interaction with *NPHP1* [Olbrich et al 2003];
- Interacts in a complex with the proteins NEK8, INVS, and ANKS6 [Hoff et al 2013];
- Plays a role in the Wnt pathway [Bergmann et al 2008];
- Localizes at the inversin compartment [Shiba et al 2010].

**Abnormal gene product.** See [Animal Models](#).

## *NPHP4*

**Gene structure.** *NPHP4* comprises 30 exons. It is expressed in ten splice variants. The largest transcript is NM\_015102, which encodes a protein of 1426 amino acids. For a detailed summary of gene and protein information, see [Table A](#), **Gene**.

**Pathogenic allelic variants.** Numerous missense, nonsense, and splicing variants and small indels have been described. Pathogenic variants are associated with isolated juvenile-onset NPH [Mollet et al 2002, Otto et al 2002] and were associated with Senior-Løken syndrome in two families homozygous for the nonsense pathogenic variants p.Arg658Ter and p.Gln779Ter [Otto et al 2002].

While there is a correlation between the presence of extrarenal features (involving the eye, liver, and developmental delay) and mutation of *NPHP4* in general, no clear correlation between the

presence of these features and a specific *NPHP4* variant type (e.g., missense, nonsense) has been found [Chaki et al 2011].

### Table 7.

#### *NPHP4* Pathogenic Variants Discussed in This *GeneReview*

DNA Nucleotide Change	Predicted Protein Change	Reference Sequences
c.1972C>T	p.Arg658Ter	<a href="#">NM_015102.4</a> <a href="#">NP_055917.1</a>
c.2335C>T	p.Gln779Ter	<a href="#">NM_015102.4</a> <a href="#">NP_055917.1</a>

Note on variant classification: Variants listed in the table have been provided by the authors. *GeneReviews* staff have not independently verified the classification of variants.

Note on nomenclature: *GeneReviews* follows the standard naming conventions of the Human Genome Variation Society ([www.hgvs.org](http://www.hgvs.org)). See [Quick Reference](#) for an explanation of nomenclature.

**Normal gene product.** *NPHP4* encodes the 1426-amino acid protein nephrocystin-4 which is part of the ciliary transition zone.

*NPHP4*:

- Contains a proline-rich region between positions 458 and 514 [Mollet et al 2005];
- Interacts with *NPHP1*, *RPGRIP1*, *RPGRIP1L*, and the tight junction-associated proteins *PALS1*, *PATJ*, and *Par6* [Mollet et al 2005, Roepman et al 2005, Arts et al 2007, Delous et al 2007, Delous et al 2009];
- May be involved in actin cytoskeleton organization at sites of cell-cell and cell-matrix adhesion [Mollet et al 2005].

**Abnormal gene product.** See [Animal Models](#).

### *IQCB1* (*NPHP5*)

**Gene structure.** *IQCB1* (*NPHP5*) consists of 15 exons and has seven alternatively spliced transcripts. The largest transcript is [NM\\_001023570](#), which encodes a protein of 598 amino acids. For a detailed summary of gene and protein information, see [Table A](#), **Gene**.

**Pathogenic allelic variants.** Biallelic missense, nonsense, and splice-site pathogenic variants and small indels in *IQCB1* are associated with Senior-Løken syndrome [Otto et al 2005] and Leber congenital amaurosis [Stone et al 2011].

The phenotype of 33 individuals with biallelic nonsense or splice-site pathogenic variants in *IQCB1* comprised juvenile NPH and early-onset retinal degeneration. None had severe central nervous system or liver anomalies [Chaki et al 2011].

**Modifier allelic variant.** The p.Ile393Asn variant, which is not associated with a renal phenotype, was identified as a modifier of *RPGR*-related retinitis pigmentosa [Fahim et al 2012].

### Table 8.

#### *IQCB1* Modifier Variants Discussed in This *GeneReview*

DNA Nucleotide Change	Predicted Protein Change	Reference Sequences
-----------------------	--------------------------	---------------------

c.1178T>A	p.Ile393Asn	NM_001023570.2 NP_001018864.2
-----------	-------------	----------------------------------

Note on variant classification: Variants listed in the table have been provided by the authors. *GeneReviews* staff have not independently verified the classification of variants.

Note on nomenclature: *GeneReviews* follows the standard naming conventions of the Human Genome Variation Society ([www.hgvs.org](http://www.hgvs.org)). See [Quick Reference](#) for an explanation of nomenclature.

**Normal gene product.** *IQCB1* encodes a protein of 598 amino acids.

IQCB1:

- Contains two putative IQ calmodulin-binding domains that flank a coiled-coil domain;
- Interacts with calmodulin-2, the retinal protein RPGR, and CEP290 [Otto et al 2005, Schäfer et al 2008];
- Localizes along the primary cilium [Otto et al 2005].

**Abnormal gene product.** See [Animal Models](#).

### **CEP290 (NPHP6)**

**Gene structure.** *CEP290 (NPHP6)* comprises 54 exons and eight splice variants. NM\_025114 is the longest transcript. For a detailed summary of gene and protein information, see [Table A, Gene](#).

**Pathogenic allelic variants.** Pathogenic variants in *CEP290* are associated with Senior-Løken syndrome, Joubert syndrome [Sayer et al 2006, Valente et al 2006], Leber congenital amaurosis [den Hollander et al 2006], Bardet-Biedl syndrome [Leitch et al 2008] and Meckel-Gruber syndrome [Baala et al 2007b].

The majority of reported *CEP290* pathogenic variants are inactivating: in a review of 112 pathogenic variants, 88 were truncating, 20 were predicted to influence splicing, and three were missense [Coppieters et al 2010].

In 26 individuals with *CEP290* biallelic pathogenic variants, 24 developed juvenile-onset NPH and two developed infantile-onset NPH; all 26 exhibited extrarenal manifestations [Chaki et al 2011].

### **Table 9.**

Selected *CEP290* Pathogenic Variants

DNA Nucleotide Change	Predicted Protein Change	Reference Sequences
c.5707A>T	p.Glu1903Ter	NM_025114.3 NP_079390.3

Note on variant classification: Variants listed in the table have been provided by the authors. *GeneReviews* staff have not independently verified the classification of variants.

Note on nomenclature: *GeneReviews* follows the standard naming conventions of the Human Genome Variation Society ([www.hgvs.org](http://www.hgvs.org)). See [Quick Reference](#) for an explanation of nomenclature.

**Normal gene product.** The centromere protein CEP290 is 2479 amino acids long.

CEP290:

- Has an N-terminal domain that activates ATF4-mediated transcription. ATF4 is a transcription factor implicated in cAMP-dependent renal cyst formation [Sayer et al 2006];
- Contains an IQCB1 binding site at amino acids 696-869 [Schäfer et al 2008];
- Interacts with CC2D2A [Gorden et al 2008].

**Abnormal gene product.** See Animal Models.

### ***TMEM67 (NPHP11)***

**Gene structure.** *TMEM67 (NPHP11)* comprises 28 exons and has 22 transcripts. The longest transcript, NM\_153704, encodes a 995-amino acid protein. For a detailed summary of gene and protein information, see Table A, Gene.

**Pathogenic allelic variants.** More than 100 pathogenic variants in *TMEM67* have been described.

Biallelic *TMEM67* pathogenic variants are associated with a variety of ciliopathies (Table 3b) ranging from NPH with hepatic fibrosis at the mild end of the spectrum (biallelic missense variants) [Otto et al 2009, Chaki et al 2011] to Joubert syndrome [Baala et al 2007b, Otto et al 2009], COACH syndrome [Verloes & Lambotte 1989, Brancati et al 2009] and Meckel-Gruber syndrome at the severe end of the spectrum (characterized by a higher prevalence of truncating variants) [Smith et al 2006, Consugar et al 2007]. Liver disease is a common feature in *TMEM67*-related disease [Otto et al 2009].

Most individuals with *TMEM67*-related NPH have juvenile NPH; the missense variants c.755T>C (p.Met252Thr) and c.1843T>C (p.Cys615Arg) were identified in an individual with infantile-onset NPH [Chaki et al 2011].

**Modifier allelic variants.** Heterozygous pathogenic variants in *TMEM67* have been proposed as modifier alleles in Bardet-Biedl syndrome [Lindstrand et al 2014, Leitch et al 2008].

### **Table 10.**

*TMEM67* Variants Discussed in This *GeneReview*

<b>Variant Classification</b>	<b>DNA Nucleotide Change</b>	<b>Predicted Protein Change</b>	<b>Reference Sequences</b>
<b>Pathogenic</b>	c.755T>C	p.Met252Thr	<u>NM_153704.5</u>
	c.1843T>C	p.Cys615Arg	
<b>Modifier</b>	c.958A>T	p.Ser320Cys	<u>NP_714915.3</u>
	c.2241G>A	p.=	

Note on variant classification: Variants listed in the table have been provided by the authors. *GeneReviews* staff have not independently verified the classification of variants.

Note on nomenclature: *GeneReviews* follows the standard naming conventions of the Human Genome Variation Society (www.hgvs.org). See Quick Reference for an explanation of nomenclature.

**Normal gene product.** *TMEM67* encodes a 995-amino acid protein that localizes to the basal body [Williams et al 2011]. *TMEM67* interacts with MKS1 and this interaction is required for normal ciliogenesis in mouse IMCD3 cells and patient-derived renal cells [Dawe et al 2007, Tammachote et al 2009].



**Abnormal gene product.** Disruption of the interaction of the C-terminus region of TMEM67 with filamin A caused defects in basal body positioning, ciliogenesis, and the Wnt signaling pathway [Adams et al 2012]. See [Animal Models](#).

## **GLIS2**

See [Table 2b](#).

### **Table 11.**

Selected *GLIS2* Pathogenic Variants

DNA Nucleotide Change	Predicted Protein Change	Reference Sequences
c.523T>C	p.Cys175Arg	<a href="#">NM_032575.2</a>
c.775+1G>T		<a href="#">NP_115964.2</a>

Note on variant classification: Variants listed in the table have been provided by the authors. *GeneReviews* staff have not independently verified the classification of variants.

Note on nomenclature: *GeneReviews* follows the standard naming conventions of the Human Genome Variation Society ([www.hgvs.org](http://www.hgvs.org)). See [Quick Reference](#) for an explanation of nomenclature.

## **RPGRIP1L**

See [Table 2b](#).

A common p.Ala229Thr allele in *RPGRIP1L* was enriched in individuals with ciliopathies involving retinitis pigmentosa compared to other ciliopathies and may represent a modifier of retinal degeneration [Khanna et al 2009].

### **Table 12.**

*RPGRIP1L* Variants Discussed in This *GeneReview*

Variant Classification	DNA Nucleotide Change	Predicted Protein Change	Reference Sequences
Modifier	c.685G>A	p.Ala229Thr	<a href="#">NM_015272.2</a> <a href="#">NP_056087.2</a>

Note on variant classification: Variants listed in the table have been provided by the authors. *GeneReviews* staff have not independently verified the classification of variants.

Note on nomenclature: *GeneReviews* follows the standard naming conventions of the Human Genome Variation Society ([www.hgvs.org](http://www.hgvs.org)). See [Quick Reference](#) for an explanation of nomenclature.

### **Additional Genetic Causes of Nephronophthisis**

Additional genes less commonly associated with nephronophthisis (see [Table 2b](#)):

- *ANKS6*
- *CEP83*
- *CEP164*
- *DCDC2*

- *IFT172*
- *NEK8*
- *SDCCAG8*
- *TTC21B*
- *WDR19*
- *ZNF423*

## References

---

### Literature Cited

1. Adams M, Simms RJ, Abdelhamed Z, Dawe HR, Szymanska K, Logan CV, Wheway G, Pitt E, Gull K, Knowles MA, Blair E, Cross SH, Sayer JA, Johnson CA. A meckelin-filamin A interaction mediates ciliogenesis. *Hum Mol Genet.* 2012;21:1272–86. [PMC free article: [PMC3284117](#)] [PubMed: [22121117](#)]
2. Airik R, Slaats GG, Guo Z, Weiss AC, Khan N, Ghosh A, Hurd TW, Bekker-Jensen S, Schröder JM, Elledge SJ, Andersen JS, Kispert A, Castelli M, Boletta A, Giles RH, Hildebrandt F. Renal-retinal ciliopathy gene *Sdccag8* regulates DNA damage response signaling. *J Am Soc Nephrol.* 2014;25:2573–83. [PMC free article: [PMC4214515](#)] [PubMed: [24722439](#)]
3. Ala-Mello S, Kivivuori SM, Ronnholm KA, Koskimies O, Siimes MA. Mechanism underlying early anaemia in children with familial juvenile nephronophthisis. *Pediatr Nephrol.* 1996;10:578–81. [PubMed: [8897559](#)]
4. Ala-Mello S, Koskimies O, Rapola J, Kaariainen H. Nephronophthisis in Finland: epidemiology and comparison of genetically classified subgroups. *Eur J Hum Genet.* 1999;7:205–211. [PubMed: [10196704](#)]
5. Arts HH, Doherty D, van Beersum SE, Parisi MA, Letteboer SJ, Gorden NT, Peters TA, Märker T, Voeselek K, Kartono A, Ozyurek H, Farin FM, Kroes HY, Wolfrum U, Brunner HG, Cremers FP, Glass IA, Knoers NV, Roepman R. Mutations in the gene encoding the basal body protein RPGRIP1L, a nephrocystin-4 interactor, cause Joubert syndrome. *Nat Genet.* 2007;39:882–88. [PubMed: [17558407](#)]
6. Arts HH, Knoers NV. Current insights into renal ciliopathies: what can genetics teach us? *Pediatr Nephrol.* 2013;28:863–74. [PMC free article: [PMC3631122](#)] [PubMed: [22829176](#)]
7. Attanasio M, Uhlenhaut NH, Sousa VH, O’Toole JF, Otto E, Anlag K, Klugmann C, Treier AC, Helou J, Sayer JA, Seelow D, Nürnberg G, Becker C, Chudley AE, Nürnberg P, Hildebrandt F, Treier M. Loss of *GLIS2* causes nephronophthisis in humans and mice by increased apoptosis and fibrosis. *Nat Genet.* 2007;39:1018–24. [PubMed: [17618285](#)]
8. Baala L, Audollent S, Martinovic J, Ozilou C, Babron MC, Sivanandamoorthy S, Saunier S, Salomon R, Gonzales M, Rattenberry E, Esculpavit C, Toutain A, Moraine C, Parent P, Marcorelles P, Dauge MC, Roume J, Le Merrer M, Meiner V, Meir K, Menez F, Beaufrère AM, Francannet C, Tantau J, Sinico M, Dumez Y, MacDonald F, Munnich A, Lyonnet S, Gubler MC, Génin E, Johnson CA, Vekemans M, Encha-Razavi F, Attié-Bitach T. Pleiotropic effects of *CEP290* (*NPHP6*) mutations extend to Meckel syndrome. *Am J Hum Genet.* 2007a;81:170–9. [PMC free article: [PMC1950929](#)] [PubMed: [17564974](#)]
9. Baala L, Romano S, Khaddour R, Saunier S, Smith UM, Audollent S, Ozilou C, Faivre L, Laurent N, Foliguet B, Munnich A, Lyonnet S, Salomon R, Encha-Razavi F, Gubler MC, Boddaert N, de Lonlay P, Johnson CA, Vekemans M, Antignac C, Attie-Bitach T.

- The Meckel-Gruber syndrome gene, MKS3, is mutated in Joubert syndrome. *Am J Hum Genet.* 2007b;80:186–94. [PMC free article: PMC1785313] [PubMed: 17160906]
10. Badano JL, Kim JC, Hoskins BE, Lewis RA, Ansley SJ, Cutler DJ, Castellan C, Beales PL, Leroux MR, Katsanis N. Heterozygous mutations in BBS1, BBS2 and BBS6 have a potential epistatic effect on Bardet-Biedl patients with two mutations at a second BBS locus. *Hum Mol Genet.* 2003;12:1651–9. [PubMed: 12837689]
  11. Baris H, Bejjani BA, Tan WH, Coulter DL, Martin JA, Storm AL, Burton BK, Saitta SC, Gajecka M, Ballif BC, Irons MB, Shaffer LG, Kimonis VE. Identification of a novel polymorphism--the duplication of the NPHP1 (nephronophthisis 1) gene. *Am J Med Genet.* 2006;140A:1876–9. [PubMed: 16892302]
  12. Barker AR, Thomas R, Dawe HR. Meckel-Gruber syndrome and the role of primary cilia in kidney, skeleton, and central nervous system development. *Organogenesis.* 2014;10:96–107. [PMC free article: PMC4049900] [PubMed: 24322779]
  13. Benzing T, Schermer B. Clinical spectrum and pathogenesis of nephronophthisis. *Curr Opin Nephrol Hypertens.* 2012;21:272–8. [PubMed: 22388554]
  14. Bergmann C, Fliegauf M, Brüche NO, Frank V, Olbrich H, Kirschner J, Schermer B, Schmedding I, Kispert A, Kränzlin B, Nürnberg G, Becker C, Grimm T, Girschick G, Lynch SA, Kelehan P, Senderek J, Neuhaus TJ, Stallmach T, Zentgraf H, Nürnberg P, Gretz N, Lo C, Lienkamp S, Schäfer T, Walz G, Benzing T, Zerres K, Omran H. Loss of nephrocystin-3 function can cause embryonic lethality, Meckel-Gruber-like syndrome, situs inversus, and renal-hepatic-pancreatic dysplasia. *Am J Hum Genet.* 2008;82:959–70. [PMC free article: PMC2427297] [PubMed: 18371931]
  15. Betz R, Rensing C, Otto E, Mincheva A, Zehnder D, Lichter P, Hildebrandt F. Children with ocular motor apraxia type Cogan carry deletions in the gene (NPHP1) for juvenile nephronophthisis. *J Pediatr.* 2000;136:828–31. [PubMed: 10839884]
  16. Billingsley G, Vincent A, Deveault C, Heon E. Mutational analysis of SDCCAG8 in Bardet-Biedl syndrome patients with renal involvement and absent polydactyly. *Ophthalmic Genet.* 2012;33:150–4. [PubMed: 22626039]
  17. Bingham C, Bulman MP, Ellard S, Allen LI, Lipkin GW, Hoff WG, Woolf AS, Rizzoni G, Novelli G, Nicholls AJ, Hattersley AT. Mutations in the hepatocyte nuclear factor-1beta gene are associated with familial hypoplastic glomerulocystic kidney disease. *Am J Hum Genet.* 2001;68:219–24. [PMC free article: PMC1234916] [PubMed: 11085914]
  18. Bizet AA, Becker-Heck A, Ryan R, Weber K, Filhol E, Krug P, Halbritter J, Delous M, Lasbennes MC, Linghu B, Oakeley EJ, Zarhrate M, Nitschké P, Garfa-Traore M, Serluca F, Yang F, Bouwmeester T, Pinson L, Cassuto E, Dubot P, Elshakhs NA, Sahel JA, Salomon R, Drummond IA, Gubler MC, Antignac C, Chibout S, Szustakowski JD, Hildebrandt F, Lorentzen E, Sailer AW, Benmerah A, Saint-Mezard P, Saunier S. Mutations in TRAF3IP1/IFT54 reveal a new role for IFT proteins in microtubule stabilization. *Nat. Commun.* 2015;6:8666. [PMC free article: PMC4617596] [PubMed: 26487268]
  19. Bleyer AJ, Hart TC. Medullary cystic disease. In: Lifton RP, Somlo S, Giebisch GH, Seldin DW, eds. *Genetic Diseases of the Kidney.* 1 ed. Vol 1. Burlington, MA: Elsevier; 2009:447-59.
  20. Blowey DL, Querfeld U, Geary D, Warady BA, Alon U. Ultrasound findings in juvenile nephronophthisis. *Pediatr Nephrol.* 1996;10:22–4. [PubMed: 8611349]
  21. Bollée G, Fakhouri F, Karras A, Noël LH, Salomon R, Servais A, Lesavre P, Morinière V, Antignac C, Hummel A. Nephronophthisis related to homozygous NPHP1 gene deletion as a cause of chronic renal failure in adults. *Nephrol Dial Transplant.* 2006;21:2660–3. [PubMed: 16782989]
  22. Brancati F, Iannicelli M, Travaglini L, Mazzotta A, Bertini E, Boltshauser E, D'Arrigo

- S, Emma F, Fazzi E, Gallizzi R, Gentile M, Loncarevic D, Mejaski-Bosnjak V, Pantaleoni C, Rigoli L, Salpietro CD, Signorini S, Stringini GR, Verloes A, Zablocka D, Dallapiccola B, Gleeson JG, Valente EM., International JSRD Study Group. MKS3/TMEM67 mutations are a major cause of COACH Syndrome, a Joubert Syndrome related disorder with liver involvement. *Hum Mutat.* 2009;30:E432–42. [PMC free article: [PMC2635428](#)] [PubMed: [19058225](#)]
23. Brancati F, Travaglini L, Zablocka D, Boltshauser E, Accorsi P, Montagna G, Silhavy JL, Barrano G, Bertini E, Emma F, Rigoli L., International JSRD Study Group. Dallapiccola B, Gleeson JG, Valente EM. RPGRIP1L mutations are mainly associated with the cerebello-renal phenotype of Joubert syndrome-related disorders. *Clin Genet.* 2008;74:164–70. [PMC free article: [PMC2752690](#)] [PubMed: [18565097](#)]
24. Braun DA, Schueler M, Halbritter J, Gee HY, Porath JD, Lawson JA, Airik R, Shril S, Allen SJ, Stein D, Al Kindy A, Beck BB, Cengiz N, Moorani KN, Ozaltin F, Hashmi S, Sayer JA, Bockenhauer D, Soliman NA, Otto EA, Lifton RP, Hildebrandt F. Whole exome sequencing identifies causative mutations in the majority of consanguineous or familial cases with childhood-onset increased renal echogenicity. *Kidney Int.* 2016;89:468–75. [PMC free article: [PMC4840095](#)] [PubMed: [26489029](#)]
25. Bredrup C, Saunier S, Oud MM, Fiskerstrand T, Hoischen A, Brackman D, Leh SM, Midtbø M, Filhol E, Bole-Feysot C, Nitschké P, Gilissen C, Haugen OH, Sanders JS, Stolte-Dijkstra I, Mans DA, Steenbergen EJ, Hamel BC, Matignon M, Pfundt R, Jeanpierre C, Boman H, Rødahl E, Veltman JA, Knappskog PM, Knoers NV, Roepman R, Arts HH. Ciliopathies with skeletal anomalies and renal insufficiency due to mutations in the IFT-A gene WDR19. *Am J Hum Genet.* 2011;89:634–43. [PMC free article: [PMC3213394](#)] [PubMed: [22019273](#)]
26. Bujakowska KM, Zhang Q, Siemiatkowska AM, Liu Q, Place E, Falk MJ, Consugar M, Lancelot ME, Antonio A, Lonjou C, Carpentier W, Mohand-Saïd S, den Hollander AI, Cremers FP, Leroy BP, Gai X, Sahel JA, van den Born LI, Collin RW, Zeitz C, Audo I, Pierce EA. Mutations in IFT172 cause isolated retinal degeneration and Bardet-Biedl syndrome. *Hum Mol Genet.* 2015;24:230–42. [PMC free article: [PMC4326328](#)] [PubMed: [25168386](#)]
27. Bullich G, Vargas I, Trujillano D, Mendizábal S, Piñero-Fernández JA, Fraga G, García-Solano J, Ballarín J, Estivill X, Torra R, Ars E. Contribution of the TTC21B gene to glomerular and cystic kidney diseases. *Nephrol Dial Transplant.* 2016. Epub ahead of print. [PubMed: [26940125](#)]
28. Caridi G, Dagnino M, Rossi A, Valente EM, Bertini E, Fazzi E, Emma F, Murer L, Verrina E, Ghiggeri GM. Nephronophthisis type 1 deletion syndrome with neurological symptoms: prevalence and significance of the association. *Kidney Int.* 2006;70:1342–7. [PubMed: [16900087](#)]
29. Caridi G, Murer L, Bellantuono R, Sorino P, Caringella DA, Gusmano R, Ghiggeri GM. Renal-retinal syndromes: association of retinal anomalies and recessive nephronophthisis in patients with homozygous deletion of the NPH1 locus. *Am J Kidney Dis.* 1998;32:1059–62. [PubMed: [9856524](#)]
30. Castori M, Valente EM, Donati MA, Salvi S, Fazzi E, Procopio E, Galluccio T, Emma F, Dallapiccola B, Bertini E., Italian MTS Study Group. NPHP1 gene deletion is a rare cause of Joubert syndrome related disorders. *J Med Genet.* 2005;42:e9. [PMC free article: [PMC1735997](#)] [PubMed: [15689444](#)]
31. Chaki M, Airik R, Ghosh AK, Giles RH, Chen R, Slaats GG, Wang H, Hurd TW, Zhou W, Cluckey A, Gee HY, Ramaswami G, Hong CJ, Hamilton BA, Cervenka I, Ganji RS, Bryja V, Arts HH, van Reeuwijk J, Oud MM, Letteboer SJ, Roepman R, Husson H, Ibraghimov-Beskrovnaya O, Yasunaga T, Walz G, Eley L, Sayer JA, Schermer B,

- Liebau MC, Benzing T, Le Corre S, Drummond I, Janssen S, Allen SJ, Natarajan S, O'Toole JF, Attanasio M, Saunier S, Antignac C, Koenekoop RK, Ren H, Lopez I, Nayir A, Stoetzel C, Dollfus H, Massoudi R, Gleeson JG, Andreoli SP, Doherty DG, Lindstrad A, Golzio C, Katsanis N, Pape L, Abboud EB, Al-Rajhi AA, Lewis RA, Omran H, Lee EY, Wang S, Sekiguchi JM, Saunders R, Johnson CA, Garner E, Vanselow K, Andersen JS, Shlomai J, Nurnberg G, Nurnberg P, Levy S, Smogorzewska A, Otto EA, Hildebrandt F. Exome capture reveals ZNF423 and CEP164 mutations, linking renal ciliopathies to DNA damage response signaling. *Cell*. 2012;150:533–48. [PMC free article: [PMC3433835](#)] [PubMed: [22863007](#)]
32. Chaki M, Hoefele J, Allen SJ, Ramaswami G, Janssen S, Bergmann C, Heckenlively JR, Otto EA, Hildebrandt F. Genotype-phenotype correlation in 440 patients with NPHP-related ciliopathies. *Kidney Int*. 2011;80:1239–45. [PMC free article: [PMC4037742](#)] [PubMed: [21866095](#)]
33. Choi HJ, Lin JR, Vannier JB, Slaats GG, Kile AC, Paulsen RD, Manning DK, Beier DR, Giles RH, Boulton SJ, Cimprich KA. NEK8 links the ATR-regulated replication stress response and S phase CDK activity to renal ciliopathies. *Mol Cell*. 2013;51:423–39. [PMC free article: [PMC3790667](#)] [PubMed: [23973373](#)]
34. Chung EM, Conran RM, Schroeder JW, Rohena-Quinquilla IR, Rooks VJ. From the radiologic pathology archives: pediatric polycystic kidney disease and other ciliopathies: radiologic-pathologic correlation. *Radiographics*. 2014;34:155–78. [PubMed: [24428289](#)]
35. Consugar MB, Kubly VJ, Lager DJ, Hommerding CJ, Wong WC, Bakker E, Gattone VH 2nd, Torres VE, Breuning MH, Harris PC. Molecular diagnostics of Meckel-Gruber syndrome highlights phenotypic differences between MKS1 and MKS3. *Hum Genet*. 2007;121:591–9. [PubMed: [17377820](#)]
36. Coppieters F, Lefever S, Leroy BP, De Baere E. CEP290, a gene with many faces: mutation overview and presentation of CEP290base. *Hum Mutat*. 2010;31:1097–108. [PubMed: [20690115](#)]
37. Coussa RG, Otto EA, Gee HY, Arthurs P, Ren H, Lopez I, Keser V, Fu Q, Faingold R, Khan A, Schwartzentruber J, Majewski J, Hildebrandt F, Koenekoop RK. WDR19: an ancient, retrograde, intraflagellar ciliary protein is mutated in autosomal recessive retinitis pigmentosa and in Senior-Loken syndrome. *Clin Genet*. 2013;84:150–9. [PMC free article: [PMC3904424](#)] [PubMed: [23683095](#)]
38. Davis EE, Zhang Q, Liu Q, Diplas BH, Davey LM, Hartley J, Stoetzel C, Szymanska K, Ramaswami G, Logan CV, Muzny DM, Young AC, Wheeler DA, Cruz P, Morgan M, Lewis LR, Cherukuri P, Maskeri B, Hansen NF, Mullikin JC, Blakesley RW, Bouffard GG, NISC Comparative Sequencing Program, Gyapay G, Rieger S, Tönshoff B, Kern I, Soliman NA, Neuhaus TJ, Swoboda KJ, Kayserili H, Gallagher TE, Lewis RA, Bergmann C, Otto EA, Saunier S, Scambler PJ, Beales PL, Gleeson JG, Maher ER, Attié-Bitach T, Dollfus H, Johnson CA, Green ED, Gibbs RA, Hildebrandt F, Pierce EA, Katsanis N. TTC21B contributes both causal and modifying alleles across the ciliopathy spectrum. *Nat Genet*. 2011;43:189–96. [PMC free article: [PMC3071301](#)] [PubMed: [21258341](#)]
39. Dawe HR, Smith UM, Cullinane AR, Gerrelli D, Cox P, Badano JL, Blair-Reid S, Sriram N, Katsanis N, Attie-Bitach T, Afford SC, Copp AJ, Kelly DA, Gull K, Johnson CA. The Meckel-Gruber Syndrome proteins MKS1 and meckelin interact and are required for primary cilium formation. *Hum Mol Genet*. 2007;16:173–86. [PubMed: [17185389](#)]
40. de Vries J, Yntema JL, van Die CE, Crama N, Cornelissen EA, Hamel BC. Jeune syndrome: description of 13 cases and a proposal for follow-up protocol. *Eur J Pediatr*.

- 2010;169:77–88. [PMC free article: PMC2776156] [PubMed: 19430947]
41. Delous M, Baala L, Salomon R, Laclef C, Vierkotten J, Tory K, Golzio C, Lacoste T, Besse L, Ozilou C, Moutkine I, Hellman NE, Anselme I, Silbermann F, Vesque C, Gerhardt C, Rattenberry E, Wolf MT, Gubler MC, Martinovic J, Encha-Razavi F, Boddaert N, Gonzales M, Macher MA, Nivet H, Champion G, Berthéléme JP, Niaudet P, McDonald F, Hildebrandt F, Johnson CA, Vekemans M, Antignac C, Rüther U, Schneider-Maunoury S, Attié-Bitach T, Saunier S. The ciliary gene RPGRIP1L is mutated in cerebello-oculo-renal syndrome (Joubert syndrome type B) and Meckel syndrome. *Nat Genet.* 2007;39:875–81. [PubMed: 17558409]
  42. Delous M, Hellman NE, Gaudé HM, Silbermann F, Le Bivic A, Salomon R, Antignac C, Saunier S. Nephrocystin-1 and nephrocystin-4 are required for epithelial morphogenesis and associate with PALS1/PATJ and Par6. *Hum Mol Genet.* 2009;18:4711–23. [PMC free article: PMC2778369] [PubMed: 19755384]
  43. den Hollander AI, Koenekoop RK, Yzer S, Lopez I, Arends ML, Voesenek KE, Zonneveld MN, Strom TM, Meitinger T, Brunner HG, Hoyng CB, van den Born LI, Rohrschneider K, Cremers FP. Mutations in the CEP290 (NPHP6) gene are a frequent cause of Leber congenital amaurosis. *Am J Hum Genet.* 2006;79:556–61. [PMC free article: PMC1559533] [PubMed: 16909394]
  44. Doherty D. Joubert syndrome: insights into brain development, cilium biology, and complex disease. *Semin Pediatr Neurol.* 2009;16:143–54. [PMC free article: PMC2804071] [PubMed: 19778711]
  45. Doherty D, Parisi MA, Finn LS, Gunay-Aygun M, Al-Mateen M, Bates D, Clericuzio C, Demir H, Dorschner M, van Essen AJ, Gahl WA, Gentile M, Gorden NT, Hikida A, Knutzen D, Ozyurek H, Phelps I, Rosenthal P, Verloes A, Weigand H, Chance PF, Dobyns WB, Glass IA. Mutations in 3 genes (MKS3, CC2D2A and RPGRIP1L) cause COACH syndrome (Joubert syndrome with congenital hepatic fibrosis). *J Med Genet.* 2010;47:8–21. [PMC free article: PMC3501959] [PubMed: 19574260]
  46. Donaldson JC, Dise RS, Ritchie MD, Hanks SK. Nephrocystin-conserved domains involved in targeting to epithelial cell-cell junctions, interaction with filamins, and establishing cell polarity. *J Biol Chem.* 2002;277:29028–35. [PubMed: 12006559]
  47. Drivas TG, Wojno AP, Tucker BA, Stone EM, Bennett J. Basal exon skipping and genetic pleiotropy: A predictive model of disease pathogenesis. *Sci Transl Med.* 2015;7:291ra97. [PMC free article: PMC4486480] [PubMed: 26062849]
  48. Fahim AT, Bowne SJ, Sullivan LS, Webb KD, Williams JT, Wheaton DK, Birch DG, Daiger SP. Polymorphic variation of RPGRIP1L and IQCB1 as modifiers of X-linked retinitis pigmentosa caused by mutations in RPGR. *Adv Exp Med Biol.* 2012;723:313–20. [PMC free article: PMC4114075] [PubMed: 22183348]
  49. Failler M, Gee HY, Krug P, Joo K, Halbritter J, Belkacem L, Filhol E, Porath JD, Braun DA, Schueler M, Frigo A, Alibeu O, Masson C, Brochard K, Hurault de Ligny B, Novo R, Pietrement C, Kayserili H, Salomon R, Gubler MC, Otto EA, Antignac C, Kim J, Benmerah A, Hildebrandt F, Saunier S. Mutations of CEP83 cause infantile nephronophthisis and intellectual disability. *Am J Hum Genet.* 2014;94:905–14. [PMC free article: PMC4121475] [PubMed: 24882706]
  50. Fliegau M, Horvath J, von Schnakenburg C, Olbrich H, Müller D, Thumfart J, Schermer B, Pazour GJ, Neumann HP, Zentgraf H, Benzing T, Omran H. Nephrocystin specifically localizes to the transition zone of renal and respiratory cilia and photoreceptor connecting cilia. *J Am Soc Nephrol.* 2006;17:2424–33. [PubMed: 16885411]
  51. Forsythe E, Beales PL. Bardet-Biedl syndrome. *Eur J Hum Genet.* 2013;21:8–13. [PMC free article: PMC3522196] [PubMed: 22713813]

52. Frank V, den Hollander AI, Brüchle NO, Zonneveld MN, Nürnberg G, Becker C, Du Bois G, Kendziorra H, Roosing S, Senderek J, Nürnberg P, Cremers FP, Zerres K, Bergmann C. Mutations of the CEP290 gene encoding a centrosomal protein cause Meckel-Gruber syndrome. *Hum Mutat.* 2008;29:45–52. [PubMed: 17705300]
53. Frank V, Habbig S, Bartram MP, Eisenberger T, Veenstra-Knol HE, Decker C, Boorsma RA, Göbel H, Nürnberg G, Griessmann A, Franke M, Borgal L, Kohli P, Völker LA, Dötsch J, Nürnberg P, Benzing T, Bolz HJ, Johnson C, Gerkes EH, Schermer B, Bergmann C. Mutations in NEK8 link multiple organ dysplasia with altered Hippo signalling and increased c-MYC expression. *Hum Mol Genet.* 2013;22:2177–85. [PubMed: 23418306]
54. Gagnadoux MF, Bacri JL, Broyer M, Habib R. Infantile chronic tubulo-interstitial nephritis with cortical microcysts: variant of nephronophthisis or new disease entity? *Pediatr Nephrol.* 1989;3:50–5. [PubMed: 2702088]
55. Garcia-Gonzalo FR, Corbit KC, Sirerol-Piquer MS, Ramaswami G, Otto EA, Noriega TR, Seol AD, Robinson JF, Bennett CL, Josifova DJ, García-Verdugo JM, Katsanis N, Hildebrandt F, Reiter JF. A transition zone complex regulates mammalian ciliogenesis and ciliary membrane composition. *Nat Genet.* 2011;43:776–84. [PMC free article: PMC3145011] [PubMed: 21725307]
56. Gerdes JM, Davis EE, Katsanis N. The vertebrate primary cilium in development, homeostasis, and disease. *Cell.* 2009;137:32–45. [PMC free article: PMC3016012] [PubMed: 19345185]
57. Gorden NT, Arts HH, Parisi MA, Coene KL, Letteboer SJ, van Beersum SE, Mans DA, Hikida A, Eckert M, Knutzen D, Alswaid AF, Ozyurek H, Dibooglu S, Otto EA, Liu Y, Davis EE, Hutter CM, Bammler TK, Farin FM, Dorschner M, Topçu M, Zackai EH, Rosenthal P, Owens KN, Katsanis N, Vincent JB, Hildebrandt F, Rubel EW, Raible DW, Knoers NV, Chance PF, Roepman R, Moens CB, Glass IA, Doherty D. CC2D2A is mutated in Joubert syndrome and interacts with the ciliopathy-associated basal body protein CEP290. *Am J Hum Genet.* 2008;83:559–571. [PMC free article: PMC2668034] [PubMed: 18950740]
58. KDIGO. Kidney Disease – Improving Global Outcomes 2012 Clinical Practice Guideline for Evaluation and Management of Chronic Kidney Disease. International Society of Nephrology. Available online. 2013. Accessed 6-20-16.
59. Haider NB, Carmi R, Shalev H, Sheffield VC, Landau D. A Bedouin kindred with infantile nephronophthisis demonstrates linkage to chromosome 9 by homozygosity mapping. *Am J Hum Genet.* 1998;63:1404–10. [PMC free article: PMC1377550] [PubMed: 9792867]
60. Halbritter J, Porath JD, Diaz KA, Braun DA, Kohl S, Chaki M, Allen SJ, Soliman NA, Hildebrandt F, Otto EA., GPN Study Group. Identification of 99 novel mutations in a worldwide cohort of 1,056 patients with a nephronophthisis-related ciliopathy. *Hum Genet.* 2013;132:865–84. [PMC free article: PMC4643834] [PubMed: 23559409]
61. Hamiwka LA, Midgley JP, Wade AW, Martz KL, Grisaru S. Outcomes of kidney transplantation in children with nephronophthisis: an analysis of the North American Pediatric Renal Trials and Collaborative Studies (NAPRTCS) Registry. *Pediatr Transplant.* 2008;12:878–82. [PubMed: 19000067]
62. Helou J, Otto EA, Attanasio M, Allen SJ, Parisi MA, Glass I, Utsch B, Hashmi S, Fazzi E, Omran H, O’Toole JF, Sayer JA, Hildebrandt F. Mutation analysis of NPHP6/CEP290 in patients with Joubert syndrome and Senior-Loken syndrome. *J Med Genet.* 2007;44:657–63. [PMC free article: PMC2597962] [PubMed: 17617513]
63. Hildebrandt F, Attanasio M, Otto E. Nephronophthisis: disease mechanisms of a ciliopathy. *J Am Soc Nephrol.* 2009;20:23–35. [PMC free article: PMC2807379]

- [PubMed: 19118152]
64. Hildebrandt F, Otto E, Rensing C, Nothwang HG, Vollmer M, Adolphs J, Hanusch H, Brandis M. A novel gene encoding an SH3 domain protein is mutated in nephronophthisis type 1. *Nat Genet.* 1997;17:149–53. [PubMed: 9326933]
  65. Hildebrandt F, Singh-Sawhney I, Schnieders B, Centofante L, Omran H, Pohlmann A, Schmaltz C, Wedekind H, Schubotz C, Antignac C, Weber JL, Brandis M. Mapping of a gene for familial juvenile nephronophthisis: refining the map and defining flanking markers on chromosome 2. APN Study Group. *Am J Hum Genet.* 1993;53:1256–61. [PMC free article: PMC1682479] [PubMed: 8250041]
  66. Hildebrandt F, Zhou W. Nephronophthisis-associated ciliopathies. *J Am Soc Nephrol.* 2007;18:1855–71. [PubMed: 17513324]
  67. Hoefele J, Nayir A, Chaki M, Imm A, Allen SJ, Otto EA, Hildebrandt F. Pseudodominant inheritance of nephronophthisis caused by a homozygous NPHP1 deletion. *Pediatr Nephrol.* 2011;26:967–71. [PMC free article: PMC3342573] [PubMed: 21258817]
  68. Hoefele J, Wolf MT, O'Toole JF, Otto EA, Schultheiss U, Dêschenes G, Attanasio M, Utsch B, Antignac C, Hildebrandt F. Evidence of oligogenic inheritance in nephronophthisis. *J Am Soc Nephrol.* 2007;18:2789–95. [PubMed: 17855640]
  69. Hoff S, Halbritter J, Epting D, Frank V, Nguyen TM, van Reeuwijk J, Boehlke C, Schell C, Yasunaga T, Helmstädter M, Mergen M, Filhol E, Boldt K, Horn N, Ueffing M, Otto EA, Eisenberger T, Elting MW, van Wijk JA, Bockenbauer D, Sebire NJ, Rittig S, Vyberg M, Ring T, Pohl M, Pape L, Neuhaus TJ, Elshakhs NA, Koon SJ, Harris PC, Grahammer F, Huber TB, Kuehn EW, Kramer-Zucker A, Bolz HJ, Roepman R, Saunier S, Walz G, Hildebrandt F, Bergmann C, Lienkamp SS. ANKS6 is a central component of a nephronophthisis module linking NEK8 to INVS and NPHP3. *Nat Genet.* 2013;45:951–6. [PMC free article: PMC3786259] [PubMed: 23793029]
  70. Hurd TW, Hildebrandt F. Mechanisms of nephronophthisis and related ciliopathies. *Nephron Exp Nephrol.* 2011;118:e9–14. [PMC free article: PMC2992643] [PubMed: 21071979]
  71. Hurd TW, Otto EA, Mishima E, Gee HY, Inoue H, Inazu M, Yamada H, Halbritter J, Seki G, Konishi M, Zhou W, Yamane T, Murakami S, Caridi G, Ghiggeri G, Abe T, Hildebrandt F. Mutation of the Mg<sup>2+</sup> transporter SLC41A1 results in a nephronophthisis-like phenotype. *J Am Soc Nephrol.* 2013;24:967–77. [PMC free article: PMC3665398] [PubMed: 23661805]
  72. Huynh Cong E, Bizet AA, Boyer O, Woerner S, Gribouval O, Filhol E, Arrondel C, Thomas S, Silbermann F, Canaud G, Hachicha J, Ben Dhia N, Peraldi MN, Harzallah K, Iftene D, Daniel L, Willems M, Noel LH, Bole-Feysot C, Nitschké P, Gubler MC, Mollet G, Saunier S, Antignac C. A Homozygous missense mutation in the ciliary gene TTC21B causes familial FSGS. *J Am Soc Nephrol.* 2014;25:2435–43. [PMC free article: PMC4214529] [PubMed: 24876116]
  73. Imhoff O, Marion V, Stoetzel C, Durand M, Holder M, Sigaudy S, Sarda P, Hamel CP, Brandt C, Dollfus H, Moulin B. Bardet-Biedl syndrome: a study of the renal and cardiovascular phenotypes in a French cohort. *Clin J Am Soc Nephrol.* 2011;6:22–9. [PMC free article: PMC3022245] [PubMed: 20876674]
  74. Katsanis N, Ansley SJ, Badano JL, Eichers ER, Lewis RA, Hoskins BE, Scambler PJ, Davidson WS, Beales PL, Lupski JR. Triallelic inheritance in Bardet-Biedl syndrome, a Mendelian recessive disorder. *Science.* 2001;293:2256–9. [PubMed: 11567139]
  75. Khaddour R, Smith U, Baala L, Martinovic J, Clavering D, Shaffiq R, Ozilou C, Cullinane A, Kyttälä M, Shalev S, Audollent S, d'Humières C, Kadhom N, Esculpavit C, Viot G, Boone C, Oien C, Encha-Razavi F, Batman PA, Bennett CP, Woods CG,



- Roume J, Lyonnet S, Génin E, Le Merrer M, Munnich A, Gubler MC, Cox P, Macdonald F, Vekemans M, Johnson CA, Attié-Bitach T. SOFFOET (Société Française de Foetopathologie). Spectrum of MKS1 and MKS3 mutations in Meckel syndrome: a genotype-phenotype correlation. *Mutation in brief #960. Hum Mutat.* 2007;28:523–4. [PubMed: 17397051]
76. Khanna H, Davis EE, Murga-Zamalloa CA, Estrada-Cuzcano A, Lopez I, den Hollander AI, Zonneveld MN, Othman MI, Waseem N, Chakarova CF, Maubaret C, Diaz-Font A, MacDonald I, Muzny DM, Wheeler DA, Morgan M, Lewis LR, Logan CV, Tan PL, Beer MA, Inglehearn CF, Lewis RA, Jacobson SG, Bergmann C, Beales PL, Attié-Bitach T, Johnson CA, Otto EA, Bhattacharya SS, Hildebrandt F, Gibbs RA, Koenekoop RK, Swaroop A, Katsanis N. A common allele in RPGRIP1L is a modifier of retinal degeneration in ciliopathies. *Nat Genet.* 2009;41:739–45. [PMC free article: PMC2783476] [PubMed: 19430481]
77. Kjaer KW, Fischer Hansen B, Keeling JW, Kjaer I. Skeletal malformations in fetuses with Meckel syndrome. *Am J Med Genet.* 1999;84:469–75. [PubMed: 10360401]
78. Kojima F, Ishida M, Tsujimoto Y, Hosomi M, Toshiaki K, Okabe H. First adult case of sporadic localized glomerulocystic kidney mimicking a tumor. *Oncol Lett.* 2015;9:2368–70. [PMC free article: PMC4467364] [PubMed: 26137072]
79. Kroes HY, Monroe GR, van der Zwaag B, Duran KJ, de Kovel CG, van Roosmalen MJ, Harakalova M, Nijman IJ, Kloosterman WP, Giles RH, Knoers NV, van Haften G. Joubert syndrome: genotyping a Northern European patient cohort. *Eur J Hum Genet.* 2016;24:214–20. [PMC free article: PMC4717206] [PubMed: 25920555]
80. Lee JM, Ahn YH, Kang HG, Ha II, Lee K, Moon KC, Lee JH, Park YS, Cho YM, Bae JS, Kim NK, Park WY, Cheong HI. Nephronophthisis 13: implications of its association with Caroli disease and altered intracellular localization of WDR19 in the kidney. *Pediatr Nephrol.* 2015;30:1451–8. [PubMed: 25726036]
81. Leitch CC, Zaghoul NA, Davis EE, Stoetzel C, Diaz-Font A, Rix S, Alfadhel M, Lewis RA, Eyaid W, Banin E, Dollfus H, Beales PL, Badano JL, Katsanis N. Hypomorphic mutations in syndromic encephalocele genes are associated with Bardet-Biedl syndrome. *Nat Genet.* 2008;40:443–8. [PubMed: 18327255]
82. Lennerz JK, Spence DC, Iskandar SS, Dehner LP, Liapis H. Glomerulocystic kidney: one hundred-year perspective. *Arch Pathol Lab Med.* 2010;134:583–605. [PubMed: 20367310]
83. Lin AE, Traum AZ, Sahai I, Keppler-Noreuil K, Kukolich MK, Adam MP, Westra SJ, Arts HH. Sensenbrenner syndrome (Cranioectodermal dysplasia): clinical and molecular analyses of 39 patients including two new patients. *Am J Med Genet A.* 2013;161A:2762–76. [PubMed: 24123776]
84. Lindstrand A, Davis EE, Carvalho CM, Pehlivan D, Willer JR, Tsai IC, Ramanathan S, Zuppan C, Sabo A, Muzny D, Gibbs R, Liu P, Lewis RA, Banin E, Lupski JR, Clark R, Katsanis N. Recurrent CNVs and SNVs at the NPHP1 locus contribute pathogenic alleles to Bardet-Biedl syndrome. *Am J Hum Genet.* 2014;94:745–54. [PMC free article: PMC4067552] [PubMed: 24746959]
85. Littink KW, Pott JW, Collin RW. A novel nonsense mutation in CEP290 induces exon skipping and leads to a relatively mild retinal phenotype. *Invest Ophthalmol Vis Sci.* 2010;51:3646–52. [PubMed: 20130272]
86. Louie CM, Caridi G, Lopes VS, Brancati F, Kispert A, Lancaster MA, Schlossman AM, Otto EA, Leitges M, Gröne HJ, Lopez I, Gudiseva HV, O'Toole JF, Vallespin E, Ayyagari R, Ayuso C, Cremers FP, den Hollander AI, Koenekoop RK, Dallapiccola B, Ghiggeri GM, Hildebrandt F, Valente EM, Williams DS, Gleeson JG. AHI1 is required for photoreceptor outer segment development and is a modifier for retinal degeneration

- in nephronophthisis. *Nat Genet.* 2010;42:175–80. [[PMC free article: PMC2884967](#)] [[PubMed: 20081859](#)]
87. Lucas-Herald AK, Kinning E, Iida A, Wang Z, Miyake N, Ikegawa S, McNeilly J, Ahmed SF. A case of functional growth hormone deficiency and early growth retardation in a child with IFT172 mutations. *J Clin Endocrinol Metab.* 2015;100:1221–4. [[PubMed: 25664603](#)]
88. McInerney-Leo AM, Harris JE, Leo PJ, Marshall MS, Gardiner B, Kinning E, Leong HY, McKenzie F, Ong WP, Vodopiutz J, Wicking C, Brown MA, Zankl A, Duncan EL. Whole exome sequencing is an efficient, sensitive and specific method for determining the genetic cause of short-rib thoracic dystrophies. *Clin Genet.* 2015;88:550–7. [[PubMed: 25492405](#)]
89. Mergen M, Engel C, Müller B, Follo M, Schäfer T, Jung M, Walz G. The nephronophthisis gene product NPHP2/Inversin interacts with Aurora A and interferes with HDAC6-mediated cilia disassembly. *Nephrol Dial Transplant.* 2013;28:2744–53. [[PubMed: 24026243](#)]
90. Molin A, Benoist G, Jeanne-Pasquier C, Elkartoufi N, Litzer J, Decamp M, Gruchy N, Durand-Malbruny M, Begorre M, Attie-Bitach T, Leporrier N. 12q21 Microdeletion in a fetus with Meckel syndrome involving CEP290/MKS4. *Eur J Med Genet.* 2013;56:580–3. [[PubMed: 23954617](#)]
91. Mollet G, Salomon R, Gribouval O, Silbermann F, Bacq D, Landthaler G, Milford D, Nayir A, Rizzoni G, Antignac C, Saunier S. The gene mutated in juvenile nephronophthisis type 4 encodes a novel protein that interacts with nephrocystin. *Nat Genet.* 2002;32:300–5. [[PubMed: 12244321](#)]
92. Mollet G, Silbermann F, Delous M, Salomon R, Antignac C, Saunier S. Characterization of the nephrocystin/nephrocystin-4 complex and subcellular localization of nephrocystin-4 to primary cilia and centrosomes. *Hum Mol Genet.* 2005;14:645–56. [[PubMed: 15661758](#)]
93. Morgan D, Eley L, Sayer J, Strachan T, Yates LM, Craighead AS, Goodship JA. Expression analyses and interaction with the anaphase promoting complex protein Apc2 suggest a role for inversin in primary cilia and involvement in the cell cycle. *Hum Mol Genet.* 2002a;11:3345–50. [[PubMed: 12471060](#)]
94. Morgan D, Goodship J, Essner JJ, Vogan KJ, Turnpenny L, Yost HJ, Tabin CJ, Strachan T. The left-right determinant inversin has highly conserved ankyrin repeat and IQ domains and interacts with calmodulin. *Hum Genet.* 2002b;110:377–84. [[PubMed: 11941489](#)]
95. Niaudet P. Clinical manifestations, diagnosis, and treatment of nephronophthisis. *UpToDate.* 2013:1-7.
96. Novarino G, Akizu N, Gleeson JG. Modeling human disease in humans: the ciliopathies. *Cell.* 2011;147:70–9. [[PMC free article: PMC3202432](#)] [[PubMed: 21962508](#)]
97. Nürnberger J, Bacallao RL, Phillips CL. Inversin forms a complex with catenins and N-cadherin in polarized epithelial cells. *Mol Biol Cell.* 2002;13:3096–106. [[PMC free article: PMC124145](#)] [[PubMed: 12221118](#)]
98. Olbrich H, Fliegau M, Hoefele J, Kispert A, Otto E, Volz A, Wolf MT, Sasmaz G, Trauer U, Reinhardt R, Sudbrak R, Antignac C, Gretz N, Walz G, Schermer B, Benzing T, Hildebrandt F, Omran H. Mutations in a novel gene, NPHP3, cause adolescent nephronophthisis, tapeto-retinal degeneration and hepatic fibrosis. *Nat Genet.* 2003;34:455–9. [[PubMed: 12872122](#)]
99. Omran H. NPHP proteins: gatekeepers of the ciliary compartment. *J Cell Biol.* 2010;190:715–7. [[PMC free article: PMC2935579](#)] [[PubMed: 20819931](#)]

100. Omran H, Fernandez C, Jung M, Häffner K, Fargier B, Villaquiran A, Waldherr R, Gretz N, Brandis M, Rüschemdorf F, Reis A, Hildebrandt F. Identification of a new gene locus for adolescent nephronophthisis, on chromosome 3q22 in a large Venezuelan pedigree. *Am J Hum Genet.* 2000;66:118–27. [PMC free article: [PMC1360127](#)] [PubMed: [10631142](#)]
101. Omran H, Sasmaz G, Häffner K, Volz A, Olbrich H, Melkaoui R, Otto E, Wienker TF, Korinthenberg R, Brandis M, Antignac C, Hildebrandt F. Identification of a gene locus for Senior-Loken syndrome in the region of the nephronophthisis type 3 gene. *J Am Soc Nephrol.* 2002;13:75–9. [PubMed: [11752023](#)]
102. O’Toole JF, Liu Y, Davis EE, Westlake CJ, Attanasio M, Otto EA, Seelow D, Nurnberg G, Becker C, Nuutinen M, Kärppä M, Ignatius J, Uusimaa J, Pakanen S, Jaakkola E, van den Heuvel LP, Fehrenbach H, Wiggins R, Goyal M, Zhou W, Wolf MT, Wise E, Helou J, Allen SJ, Murga-Zamalloa CA, Ashraf S, Chaki M, Heeringa S, Chernin G, Hoskins BE, Chaib H, Gleeson J, Kusakabe T, Suzuki T, Isaac RE, Quarmby LM, Tennant B, Fujioka H, Tuominen H, Hassinen I, Lohi H, van Houten JL, Rotig A, Sayer JA, Rolinski B, Freisinger P, Madhavan SM, Herzer M, Madignier F, Prokisch H, Nurnberg P, Jackson PK, Khanna H, Katsanis N, Hildebrandt F. Individuals with mutations in XPNPEP3, which encodes a mitochondrial protein, develop a nephronophthisis-like nephropathy. *J Clin Invest.* 2010;120:791–802. [PMC free article: [PMC2827951](#)] [PubMed: [20179356](#)]
103. O’Toole JF, Otto EA, Frishberg Y, Hildebrandt F. Retinitis pigmentosa and renal failure in a patient with mutations in INVS. *Nephrol Dial Transplant.* 2006;21:1989–91. [PubMed: [16522655](#)]
104. Otto EA, Helou J, Allen SJ, O’Toole JF, Wise EL, Ashraf S, Attanasio M, Zhou W, Wolf MT, Hildebrandt F. Mutation analysis in nephronophthisis using a combined approach of homozygosity mapping, CEL I endonuclease cleavage, and direct sequencing. *Hum Mutat.* 2008;29:418–26. [PubMed: [18076122](#)]
105. Otto E, Hoefele J, Ruf R, Mueller AM, Hiller KS, Wolf MT, Schuermann MJ, Becker A, Birkenhäger R, Sudbrak R, Hennies HC, Nürnberg P, Hildebrandt F. A gene mutated in nephronophthisis and retinitis pigmentosa encodes a novel protein, nephroretinin, conserved in evolution. *Am J Hum Genet.* 2002;71:1161–7. [PMC free article: [PMC385091](#)] [PubMed: [12205563](#)]
106. Otto EA, Hurd TW, Airik R, Chaki M, Zhou W, Stoetzel C, Patil SB, Levy S, Ghosh AK, Murga-Zamalloa CA, van Reeuwijk J, Letteboer SJ, Sang L, Giles RH, Liu Q, Coene KL, Estrada-Cuzcano A, Collin RW, McLaughlin HM, Held S, Kasanuki JM, Ramaswami G, Conte J, Lopez I, Washburn J, Macdonald J, Hu J, Yamashita Y, Maher ER, Guay-Woodford LM, Neumann HP, Obermüller N, Koenekoop RK, Bergmann C, Bei X, Lewis RA, Katsanis N, Lopes V, Williams DS, Lyons RH, Dang CV, Brito DA, Dias MB, Zhang X, Cavalcoli JD, Nürnberg G, Nürnberg P, Pierce EA, Jackson PK, Antignac C, Saunier S, Roepman R, Dollfus H, Khanna H, Hildebrandt F. Candidate exome capture identifies mutation of SDCCAG8 as the cause of a retinal-renal ciliopathy. *Nat Genet.* 2010;42:840–50. [PMC free article: [PMC2947620](#)] [PubMed: [20835237](#)]
107. Otto EA, Loeys B, Khanna H, Hellemans J, Sudbrak R, Fan S, Muerb U, O’Toole JF, Helou J, Attanasio M, Utsch B, Sayer JA, Lillo C, Jimeno D, Coucke P, De Paepe A, Reinhardt R, Klages S, Tsuda M, Kawakami I, Kusakabe T, Omran H, Imm A, Tippens M, Raymond PA, Hill J, Beales P, He S, Kispert A, Margolis B, Williams DS, Swaroop A, Hildebrandt F. Nephrocystin-5, a ciliary IQ domain protein, is mutated in Senior-Loken syndrome and interacts with RPGR and calmodulin. *Nat Genet.* 2005;37:282–8. [PubMed: [15723066](#)]

108. Otto EA, Ramaswami G, Janssen S, Chaki M, Allen SJ, Zhou W, Airik R, Hurd TW, Ghosh AK, Wolf MT, Hoppe B, Neuhaus TJ, Bockenhauer D, Milford DV, Soliman NA, Antignac C, Saunier S, Johnson CA, Hildebrandt F., GPN Study Group. Mutation analysis of 18 nephronophthisis associated ciliopathy disease genes using a DNA pooling and next generation sequencing strategy. *J Med Genet.* 2011;48:105–16. [PMC free article: [PMC3913043](#)] [PubMed: [21068128](#)]
109. Otto EA, Schermer B, Obara T, O'Toole JF, Hiller KS, Mueller AM, Ruf RG, Hoefele J, Beekmann F, Landau D, Foreman JW, Goodship JA, Strachan T, Kispert A, Wolf MT, Gagnadoux MF, Nivet H, Antignac C, Walz G, Drummond IA, Benzing T, Hildebrandt F. Mutations in INVS encoding inversin cause nephronophthisis type 2, linking renal cystic disease to the function of primary cilia and left-right axis determination. *Nat Genet.* 2003;34:413–20. [PMC free article: [PMC3732175](#)] [PubMed: [12872123](#)]
110. Otto EA, Tory K, Attanasio M, Zhou W, Chaki M, Paruchuri Y, Wise EL, Wolf MT, Utsch B, Becker C, Nürnberg G, Nürnberg P, Nayir A, Saunier S, Antignac C, Hildebrandt F. Hypomorphic mutations in meckelin (MKS3/TMEM67) cause nephronophthisis with liver fibrosis (NPHP11). *J Med Genet.* 2009;46:663–70. [PubMed: [19508969](#)]
111. Oud MM, van Bon BW, Bongers EM, Hoischen A, Marcelis CL, de Leeuw N, Mol SJ, Mortier G, Knoers NV, Brunner HG, Roepman R, Arts HH. Early presentation of cystic kidneys in a family with a homozygous INVS mutation. *Am J Med Genet A.* 2014;164A:1627–34. [PubMed: [24677454](#)]
112. Parisi MA. Clinical and molecular features of Joubert syndrome and related disorders. *Am J Med Genet C Semin Med Genet.* 2009;151C:326–40. [PMC free article: [PMC2797758](#)] [PubMed: [19876931](#)]
113. Parisi MA, Bennett CL, Eckert ML, Dobyns WB, Gleeson JG, Shaw DW, McDonald R, Eddy A, Chance PF, Glass IA. The NPHP1 gene deletion associated with juvenile nephronophthisis is present in a subset of individuals with Joubert syndrome. *Am J Hum Genet.* 2004;75:82–91. [PMC free article: [PMC1182011](#)] [PubMed: [15138899](#)]
114. Parisi MA, Doherty D, Chance PF, Glass IA. Joubert syndrome (and related disorders) (OMIM 213300). *Eur J Hum Genet.* 2007;15:511–21. [PubMed: [17377524](#)]
115. Perrault I, Halbritter J, Porath JD, Gérard X, Braun DA, Gee HY, Fathy HM, Saunier S, Cormier-Daire V, Thomas S, Attié-Bitach T, Boddaert N, Taschner M, Schueler M, Lorentzen E, Lifton RP, Lawson JA, Garfa-Traore M, Otto EA, Bastin P, Caillaud C, Kaplan J, Rozet JM, Hildebrandt F. IFT81, encoding an IFT-B core protein, as a very rare cause of a ciliopathy phenotype. *J Med Genet.* 2015;52:657–65. [PMC free article: [PMC4621372](#)] [PubMed: [26275418](#)]
116. Perrault I, Saunier S, Hanein S, Filhol E, Bizet AA, Collins F, Salih MA, Gerber S, Delphin N, Bigot K, Orssaud C, Silva E, Baudouin V, Oud MM, Shannon N, Le Merrer M, Roche O, Pietrement C, Goumid J, Baumann C, Bole-Feysot C, Nitschke P, Zahrate M, Beales P, Arts HH, Munnich A, Kaplan J, Antignac C, Cormier-Daire V, Rozet JM. Mainzer-Saldino syndrome is a ciliopathy caused by IFT140 mutations. *Am J Hum Genet.* 2012;90:864–70. [PMC free article: [PMC3376548](#)] [PubMed: [22503633](#)]
117. Piccoli GB, Cabiddu G, Attini R, Vigotti F, Fassio F, Rolfo A, Giuffrida D, Pani A, Gaglioti P, Todros T. Pregnancy in chronic kidney disease: questions and answers in a changing panorama. *Best Pract Res Clin Obstet Gynaecol.* 2015;29:625–42. [PubMed: [25825329](#)]
118. Pistor K, Olbing H, Scharer K. Children with chronic renal failure in the Federal Republic of Germany: I. Epidemiology, modes of treatment, survival. *Arbeitsgemeinschaft fur Padiatrische Nephrologie. Clin Nephrol.* 1985;23:272–7. [PubMed: [3896599](#)]

119. Rampoldi L, Caridi G, Santon D, Boaretto F, Bernascone I, Lamorte G, Tardanico R, Dagnino M, Colussi G, Scolari F, Ghiggeri GM, Amoroso A, Casari G. Allelism of MCKD, FJHN and GCKD caused by impairment of uromodulin export dynamics. *Hum Mol Genet.* 2003;12:3369–84. [PubMed: 14570709]
120. Roepman R, Letteboer SJ, Arts HH, van Beersum SE, Lu X, Krieger E, Ferreira PA, Cremers FP. Interaction of nephrocystin-4 and RPGRIP1 is disrupted by nephronophthisis or Leber congenital amaurosis-associated mutations. *Proc Natl Acad Sci U S A.* 2005;102:18520–5. [PMC free article: PMC1317916] [PubMed: 16339905]
121. Salomon R, Saunier S, Niaudet P. Nephronophthisis. *Pediatr Nephrol.* 2009;24:2333–44. [PMC free article: PMC2770134] [PubMed: 18607645]
122. Sang L, Miller JJ, Corbit KC, Giles RH, Brauer MJ, Otto EA, Baye LM, Wen X, Scales SJ, Kwong M, Huntzicker EG, Sfakianos MK, Sandoval W, Bazan JF, Kulkarni P, Garcia-Gonzalo FR, Seol AD, O'Toole JF, Held S, Reutter HM, Lane WS, Rafiq MA, Noor A, Ansar M, Devi AR, Sheffield VC, Slusarski DC, Vincent JB, Doherty DA, Hildebrandt F, Reiter JF, Jackson PK. Mapping the NPHP-JBTS-MKS protein network reveals ciliopathy disease genes and pathways. *Cell.* 2011;145:513–28. [PMC free article: PMC3383065] [PubMed: 21565611]
123. Saunier S, Calado J, Benessy F, Silbermann F, Heilig R, Weissenbach J, Antignac C. Characterization of the NPHP1 locus: mutational mechanism involved in deletions in familial juvenile nephronophthisis. *Am J Hum Genet.* 2000;66:778–89. [PMC free article: PMC1288163] [PubMed: 10712196]
124. Saunier S, Calado J, Heilig R, Silbermann F, Benessy F, Morin G, Konrad M, Broyer M, Gubler MC, Weissenbach J, Antignac C. A novel gene that encodes a protein with a putative src homology 3 domain is a candidate gene for familial juvenile nephronophthisis. *Hum Mol Genet.* 1997;6:2317–23. [PubMed: 9361039]
125. Sayer JA, Otto EA, O'Toole JF, Nurnberg G, Kennedy MA, Becker C, Hennies HC, Helou J, Attanasio M, Fausett BV, Utsch B, Khanna H, Liu Y, Drummond I, Kawakami I, Kusakabe T, Tsuda M, Ma L, Lee H, Larson RG, Allen SJ, Wilkinson CJ, Nigg EA, Shou C, Lillo C, Williams DS, Hoppe B, Kemper MJ, Neuhaus T, Parisi MA, Glass IA, Petry M, Kispert A, Gloy J, Ganner A, Walz G, Zhu X, Goldman D, Nurnberg P, Swaroop A, Leroux MR, Hildebrandt F. The centrosomal protein nephrocystin-6 is mutated in Joubert syndrome and activates transcription factor ATF4. *Nat Genet.* 2006;38:674–81. [PubMed: 16682973]
126. Schaefer E, Zaloszczyk A, Lauer J, Durand M, Stutzmann F, Perdomo-Trujillo Y, Redin C, Bennouna Greene V, Toutain A, Perrin L, Gérard M, Caillard S, Bei X, Lewis RA, Christmann D, Letsch J, Kribs M, Mutter C, Muller J, Stoetzel C, Fischbach M, Marion V, Katsanis N, Dollfus H. Mutations in SDCCAG8/NPHP10 cause Bardet-Biedl syndrome and are associated with penetrant renal disease and absent polydactyly. *Mol Syndromol.* 2011;1:273–81. [PMC free article: PMC3214956] [PubMed: 22190896]
127. Schäfer T, Putz M, Lienkamp S, Ganner A, Bergbreiter A, Ramachandran H, Gieloff V, Gerner M, Mattonet C, Czarnecki PG, Sayer JA, Otto EA, Hildebrandt F, Kramer-Zucker A, Walz G. Genetic and physical interaction between the NPHP5 and NPHP6 gene products. *Hum Mol Genet.* 2008;17:3655–62. [PMC free article: PMC2802281] [PubMed: 18723859]
128. Schmidts M, Frank V, Eisenberger T, Al Turki S, Bizet AA, Antony D, Rix S, Decker C, Bachmann N, Bald M, Vinke T, Toenshoff B, Di Donato N, Neuhann T, Hartley JL, Maher ER, Bogdanović R, Peco-Antić A, Mache C, Hurles ME, Joksić I, Guć-Šćekić M, Dobricic J, Brankovic-Magic M, Bolz HJ, Pazour GJ, Beales PL, Scambler PJ, Saunier S, Mitchison HM, Bergmann C. Combined NGS approaches identify mutations in the intraflagellar transport gene IFT140 in skeletal ciliopathies with early progressive

- kidney disease. *Hum Mutat.* 2013;34:714–24. [PMC free article: PMC4226634] [PubMed: 23418020]
129. Schön P, Tsuchiya K, Lenoir D, Mochizuki T, Guichard C, Takai S, Maiti AK, Nihei H, Weil J, Yokoyama T, Bouvagnet P. Identification, genomic organization, chromosomal mapping and mutation analysis of the human INV gene, the ortholog of a murine gene implicated in left-right axis development and biliary atresia. *Hum Genet.* 2002;110:157–65. [PubMed: 11935322]
130. Schueler M, Braun DA, Chandrasekar G, Gee HY, Klasson TD, Halbritter J, Bieder A, Porath JD, Airik R, Zhou W, LoTurco JJ, Che A, Otto EA, Böckenhauer D, Sebire NJ, Honzik T, Harris PC, Koon SJ, Gunay-Aygun M, Saunier S, Zerres K, Bruechle NO, Drenth JP, Pelletier L, Tapia-Páez I, Lifton RP, Giles RH, Kere J, Hildebrandt F. DCDC2 mutations cause a renal-hepatic ciliopathy by disrupting Wnt signaling. *Am J Hum Genet.* 2015;96:81–92. [PMC free article: PMC4289677] [PubMed: 25557784]
131. Schueler M, Halbritter J, Phelps IG, Braun DA, Otto EA, Porath JD, Gee HY, Shendure J, O'Roak BJ, Lawson JA, Nabhan MM, Soliman NA, Doherty D, Hildebrandt F. Large-scale targeted sequencing comparison highlights extreme genetic heterogeneity in nephronophthisis-related ciliopathies. *J Med Genet.* 2016;53:208–14. [PubMed: 26673778]
132. Schuermann MJ, Otto E, Becker A, Saar K, Rüschemdorf F, Polak BC, Ala-Mello S, Hoefele J, Wiedensohler A, Haller M, Omran H, Nürnberg P, Hildebrandt F. Mapping of gene loci for nephronophthisis type 4 and Senior-Loken syndrome, to chromosome 1p36. *Am J Hum Genet.* 2002;70:1240–6. [PMC free article: PMC447598] [PubMed: 11920287]
133. Scolari F, Ghiggeri GM. Nephronophthisis-medullary cystic kidney disease: from bedside to bench and back again. *Saudi J Kidney Dis Transpl.* 2003;14:316–27. [PubMed: 17657103]
134. Shiba D, Manning DK, Koga H, Beier DR, Yokoyama T. Inv acts as a molecular anchor for Nphp3 and Nek8 in the proximal segment of primary cilia. *Cytoskeleton (Hoboken)* 2010;67:112–9. [PubMed: 20169535]
135. Simms RJ, Hynes AM, Eley L, Sayer JA. Nephronophthisis: a genetically diverse ciliopathy. *Int J Nephrol.* 2011;2011:527137.
136. Simons M, Gloy J, Ganner A, Bullerkotte A, Bashkurov M, Krönig C, Schermer B, Benzing T, Cabello OA, Jenny A, Mlodzik M, Polok B, Driever W, Obara T, Walz G. Inversin, the gene product mutated in nephronophthisis type II, functions as a molecular switch between Wnt signaling pathways. *Nat Genet.* 2005;37:537–43. [PMC free article: PMC3733333] [PubMed: 15852005]
137. Simpson MA, Cross HE, Cross L, Helmuth M, Crosby AH. Lethal cystic kidney disease in Amish neonates associated with homozygous nonsense mutation of NPHP3. *Am J Kidney Dis.* 2009;53:790–5. [PubMed: 19303681]
138. Slaats GG, Ghosh AK, Falke LL, Le Corre S, Shaltiel IA, van de Hoek G, Klasson TD, Stokman MF, Logister I, Verhaar MC, Goldschmeding R, Nguyen TQ, Drummond IA, Hildebrandt F, Giles RH. Nephronophthisis-associated CEP164 regulates cell cycle progression, apoptosis and epithelial-to-mesenchymal transition. *PLoS Genet.* 2014;10:e1004594. [PMC free article: PMC4207587] [PubMed: 25340510]
139. Slaats GG, Giles RH. Are renal ciliopathies (replication) stressed out? *Trends Cell Biol.* 2015;25:317–9. [PubMed: 25937400]
140. Slaats GG, Saldivar JC, Bacal J, Zeman MK, Kile AC, Hynes AM, Srivastava S, Nazmutdinova J, den Ouden K, Zagers MS, Foletto V, Verhaar MC, Miles C, Sayer JA, Cimprich KA, Giles RH. DNA replication stress underlies renal phenotypes in CEP290-associated Joubert syndrome. *J. Clin. Invest.* 2015;125:3657–66. [PMC free article:

141. Smith UM, Consugar M, Tee LJ, McKee BM, Maina EN, Whelan S, Morgan NV, Goranson E, Gissen P, Lilliquist S, Aligianis IA, Ward CJ, Pasha S, Punyashthiti R, Malik Sharif S, Batman PA, Bennett CP, Woods CG, McKeown C, Bucourt M, Miller CA, Cox P, Algazali L, Trembath RC, Torres VE, Attie-Bitach T, Kelly DA, Maher ER, Gattone VH 2nd, Harris PC, Johnson CA. The transmembrane protein meckelin (MKS3) is mutated in Meckel-Gruber syndrome and the wpk rat. *Nat Genet.* 2006;38:191–6. [PubMed: 16415887]
142. Smyth A, Radovic M, Garovic VD. Women, kidney disease, and pregnancy. *Adv Chronic Kidney Dis.* 2013;20:402–10. [PMC free article: PMC3763929] [PubMed: 23978545]
143. Soliman NA, Hildebrandt F, Otto EA, Nabhan MM, Allen SJ, Badr AM, Sheba M, Fadda S, Gawdat G, El-Kiky H. Clinical characterization and NPHP1 mutations in nephronophthisis and associated ciliopathies: a single center experience. *Saudi J Kidney Dis Transpl.* 2012;23:1090–8. [PMC free article: PMC4154542] [PubMed: 22982934]
144. Stone EM, Cideciyan AV, Aleman TS, Scheetz TE, Sumaroka A, Ehlinger MA, Schwartz SB, Fishman GA, Traboulsi EI, Lam BL, Fulton AB, Mullins RF, Sheffield VC, Jacobson SG. Variations in NPHP5 in patients with nonsyndromic leber congenital amaurosis and Senior-Loken syndrome. *Arch Ophthalmol.* 2011;129:81–7. [PMC free article: PMC3952880] [PubMed: 21220633]
145. Tammachote R, Hommerding CJ, Sindors RM, Miller CA, Czarnecki PG, Leightner AC, Salisbury JL, Ward CJ, Torres VE, Gattone VH 2nd, Harris PC. Ciliary and centrosomal defects associated with mutation and depletion of the Meckel syndrome genes MKS1 and MKS3. *Hum Mol Genet.* 2009;18:3311–23. [PMC free article: PMC2733821] [PubMed: 19515853]
146. Taskiran EZ, Korkmaz E, Gucer S, Kosukcu C, Kaymaz F, Koyunlar C, Bryda EC, Chaki M, Lu D, Vadnagara K, Candan C, Topaloglu R, Schaefer F, Attanasio M, Bergmann C, Ozaltin F. Mutations in ANKS6 cause a nephronophthisis-like phenotype with ESRD. *J Am Soc Nephrol.* 2014;25:1653–61. [PMC free article: PMC4116054] [PubMed: 24610927]
147. Tory K, Lacoste T, Burglen L, Morinière V, Boddaert N, Macher MA, Llanas B, Nivet H, Bensman A, Niaudet P, Antignac C, Salomon R, Saunier S. High NPHP1 and NPHP6 mutation rate in patients with Joubert syndrome and nephronophthisis: potential epistatic effect of NPHP6 and AHI1 mutations in patients with NPHP1 mutations. *J Am Soc Nephrol.* 2007;18:1566–75. [PubMed: 17409309]
148. Tory K, Rousset-Rouvière C, Gubler MC, Morinière V, Pawtowski A, Becker C, Guyot C, Gié S, Frishberg Y, Nivet H, Deschênes G, Cochat P, Gagnadoux MF, Saunier S, Antignac C, Salomon R. Mutations of NPHP2 and NPHP3 in infantile nephronophthisis. *Kidney Int.* 2009;75:839–47. [PubMed: 19177160]
149. Travaglini L, Brancati F, Attie-Bitach T, Audollent S, Bertini E, Kaplan J, Perrault I, Iannicelli M, Mancuso B, Rigoli L, Rozet JM, Swistun D, Tolentino J, Dallapiccola B, Gleeson JG, Valente EM., International JSRD Study Group. Zankl A, Leventer R, Grattan-Smith P, Janecke A, D'Hooghe M, Sznajder Y, Van Coster R, Demerleir L, Dias K, Moco C, Moreira A, Kim CA, Maegawa G, Petkovic D, Abdel-Salam GM, Abdel-Aleem A, Zaki MS, Marti I, Quijano-Roy S, Sigaudy S, de Lonlay P, Romano S, Touraine R, Koenig M, Lagier-Tourenne C, Messer J, Collignon P, Wolf N, Philippi H, Kitsiou Tzeli S, Halldorsson S, Johannsdottir J, Ludvigsson P, Phadke SR, Udani V, Stuart B, Magee A, Lev D, Michelson M, Ben-Zeev B, Fischetto R, Benedicenti F, Stanzial F, Borgatti R, Accorsi P, Battaglia S, Fazzi E, Giordano L, Pinelli L, Boccone L, Bigoni S, Ferlini A, Donati MA, Caridi G, Divizia MT, Faravelli F, Ghiggeri G,

- Pessagno A, Briguglio M, Briuglia S, Salpietro CD, Tortorella G, Adami A, Castorina P, Lalatta F, Marra G, Riva D, Scelsa B, Spaccini L, Uziel G, Del Giudice E, Laverda AM, Ludwig K, Permunionian A, Suppiej A, Signorini S, Uggetti C, Battini R, Di Giacomo M, Cilio MR, Di Sabato ML, Leuzzi V, Parisi P, Pollazzon M, Silengo M, De Vescovi R, Greco D, Romano C, Cazzagon M, Simonati A, Al-Tawari AA, Bastaki L, Mégarbané A, Sabolic Avramovska V, de Jong MM, Stromme P, Koul R, Rajab A, Azam M, Barbot C, Martorell Sampol L, Rodriguez B, Pascual-Castroviejo I, Teber S, Anlar B, Comu S, Karaca E, Kayserili H, Yüksel A, Akcakus M, Al Gazali L, Sztriha L, Nicholl D, Woods CG, Bennett C, Hurst J, Sheridan E, Barnicoat A, Hennekam R, Lees M, Blair E, Bernes S, Sanchez H, Clark AE, DeMarco E, Donahue C, Sherr E, Hahn J, Sanger TD, Gallager TE, Dobyns WB, Daugherty C, Krishnamoorthy KS, Sarco D, Walsh CA, McKanna T, Milisa J, Chung WK, De Vivo DC, Raynes H, Schubert R, Seward A, Brooks DG, Goldstein A, Caldwell J, Finsecke E, Maria BL, Holden K, Cruse RP, Swoboda KJ, Viskochil D. Expanding CEP290 mutational spectrum in ciliopathies. *Am J Med Genet A*. 2009;149A:2173–80. [PMC free article: [PMC4340070](#)] [PubMed: [19764032](#)]
150. Valente EM, Brancati F, Dallapiccola B. Genotypes and phenotypes of Joubert syndrome and related disorders. *Eur J Med Genet*. 2008;51:1–23. [PubMed: [18164675](#)]
151. Valente EM, Silhavy JL, Brancati F, Barrano G, Krishnaswami SR, Castori M, Lancaster MA, Boltshauser E, Boccone L, Al-Gazali L, Fazzi E, Signorini S, Louie CM, Bellacchio E., International Joubert Syndrome Related Disorders Study Group. Bertini E, Dallapiccola B, Gleeson JG. Mutations in CEP290, which encodes a centrosomal protein, cause pleiotropic forms of Joubert syndrome. *Nat Genet*. 2006;38:623–5. [PubMed: [16682970](#)]
152. van Reeuwijk J, Arts HH, Roepman R. Scrutinizing ciliopathies by unraveling ciliary interaction networks. *Hum Mol Genet*. 2011;20:R149–57. [PubMed: [21862450](#)]
153. Verloes A, Lambotte C. Further delineation of a syndrome of cerebellar vermis hypo/aplasia, oligophrenia, congenital ataxia, coloboma, and hepatic fibrosis. *Am J Med Genet*. 1989;32:227–32. [PubMed: [2929661](#)]
154. Waldherr R, Lennert T, Weber HP, Fodisch HJ, Scharer K. The nephronophthisis complex. A clinicopathologic study in children. *Virchows Arch A Pathol Anat Histol*. 1982;394:235–54. [PubMed: [7072145](#)]
155. Waters AM, Beales PL. Ciliopathies: an expanding disease spectrum. *Pediatr Nephrol*. 2011;26:1039–56. [PMC free article: [PMC3098370](#)] [PubMed: [21210154](#)]
156. Williams CL, Li C, Kida K, Inglis PN, Mohan S, Semenc L, Bialas NJ, Stupay RM, Chen N, Blacque OE, Yoder BK, Leroux MR. MKS and NPHP modules cooperate to establish basal body/transition zone membrane associations and ciliary gate function during ciliogenesis. *J Cell Biol*. 2011;192:1023–41. [PMC free article: [PMC3063147](#)] [PubMed: [21422230](#)]
157. Wilson TA, Rose SR, Cohen P, Rogol AD, Backeljauw P, Brown R, Hardin DS, Kemp SF, Lawson M, Radovick S, Rosenthal SM, Silverman L, Speiser P., Lawson Wilkins Pediatric Endocrinology Society Drug and Therapeutics Committee. Update of guidelines for the use of growth hormone in children: the Lawson Wilkins Pediatric Endocrinology Society Drug and Therapeutics Committee. *J Pediatr*. 2003;143:415–21. [PubMed: [14571209](#)]
158. Wolf MT. Nephronophthisis and related syndromes. *Curr Opin Pediatr*. 2015;27:201–11. [PMC free article: [PMC4422489](#)] [PubMed: [25635582](#)]
159. Wolf MT, Hildebrandt F. Nephronophthisis. *Pediatr Nephrol*. 2011;26:181–94. [PMC free article: [PMC4160028](#)] [PubMed: [20652329](#)]
160. Wolf MT, Saunier S, O’Toole JF, Wanner N, Groshong T, Attanasio M, Salomon R, Stallmach T, Sayer JA, Waldherr R, Griebel M, Oh J, Neuhaus TJ, Josefiak U, Antignac



- C, Otto EA, Hildebrandt F. Mutational analysis of the RPGRIP1L gene in patients with Joubert syndrome and nephronophthisis. *Kidney Int.* 2007;72:1520–6. [PubMed: 17960139]
161. Xu M, Yang L, Wang F, Li H, Wang X, Wang W, Ge Z, Wang K, Zhao L, Li H, Li Y, Sui R, Chen R. Mutations in human IFT140 cause non-syndromic retinal degeneration. *Hum Genet.* 2015;134:1069–78. [PMC free article: PMC4565766] [PubMed: 26216056]
162. Yasuda Y, Hashimoto R, Fukai R, Okamoto N, Hiraki Y, Yamamori H, Fujimoto M, Ohi K, Taniike M, Mohri I, Nakashima M, Tsurusaki Y, Saitsu H, Matsumoto N, Miyake N, Takeda M. Duplication of the NPHP1 gene in patients with autism spectrum disorder and normal intellectual ability: a case series. *Ann Gen Psychiatry.* 2014;13:22. [PMC free article: PMC4131154] [PubMed: 25126106]
163. Yu J, Carroll TJ, McMahon AP. Sonic hedgehog regulates proliferation and differentiation of mesenchymal cells in the mouse metanephric kidney. *Development.* 2002;129:5301–12. [PubMed: 12399320]
164. Yuan S, Sun Z. Expanding horizons: ciliary proteins reach beyond cilia. *Annu Rev Genet.* 2013;47:353–76. [PubMed: 24016188]
165. Zalli D, Bayliss R, Fry AM. The Nek8 protein kinase, mutated in the human cystic kidney disease nephronophthisis, is both activated and degraded during ciliogenesis. *Hum Mol Genet.* 2012;21:1155–71. [PMC free article: PMC3277313] [PubMed: 22106379]
166. Zhang Y, Seo S, Bhattarai S, Bugge K, Searby CC, Zhang Q, Drack AV, Stone EM, Sheffield VC. BBS mutations modify phenotypic expression of CEP290-related ciliopathies. *Hum Mol Genet.* 2014;23:40–51. [PMC free article: PMC3857943] [PubMed: 23943788]
167. Zollinger HU, Mihatsch MJ, Edefonti A, Gaboardi F, Imbasciati E, Lennert T. Nephronophthisis (medullary cystic disease of the kidney). A study using electron microscopy, immunofluorescence, and a review of the morphological findings. *Helv Paediatr Acta.* 1980;35:509–30. [PubMed: 7009503]

## Chapter Notes

---

### Author Notes

This work was funded by a grant from the Dutch Kidney Foundation (CP11.18 “KOUNCIL” to Dr N Knoers). The KOUNCIL project aims to unravel the genetics and pathophysiologic mechanisms underlying nephronophthisis and –related ciliopathies.

Website: [www.kouncil.nl](http://www.kouncil.nl)

### Acknowledgments

We are grateful to the nephronophthisis patients and their families for participating in the KOUNCIL study. We also thank Dr R Giles, Dr N van de Kar, Dr A van Eerde, Dr K Renkema, Dr E Bongers and Dr H Arts for their valuable clinical and scientific contribution.

### Revision History

- 23 June 2016 (bp) Overview posted live
- 7 August 2015 (ms) Original submission

Copyright © 1993-2016, University of Washington, Seattle. All rights reserved.

For more information, see the [GeneReviews Copyright Notice and Usage Disclaimer](#).

For questions regarding permissions: [admasst@uw.edu](mailto:admasst@uw.edu).

